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ABSTRACT

New active pharmaceutical ingredients (APIs) continue to be discovered from the
natural world. These compounds can be further developed into a range of useful
products such as drugs, supplements, or cosmeceuticals. To determine the biological
target of the API, the new compounds are evaluated for their biological activity through a
combination of in silico, in vitro, and in vivo analyses. These results will determine where
the molecular target tissue is located for the API. However, identification of the target is
only the beginning of pharmaceutical and cosmeceutical development. A common
roadblock in the development of products is the evaluation and manipulation of the
permeability of an API through biologically relevant membranes.
Multiple in vitro methods to assess permeability have been developed to predict
how APIs will interact with membranes such as the gut, skin, and blood brain barrier
(BBB). Utilizing a combination of prediction methods for APIs can allow early indication
of drug likelihood, including fundamental permeability factors such as LogP, the measure
of lipophilicity. Additionally, the physicochemical properties of the molecule of interest
can be evaluated to compare the attributes of the API to other drugs and supplements.
Natural product libraries of varying complexity were evaluated for biological
activity followed by permeability analysis and drug likeliness. Samples include crude
plant extracts, pre-chromatography fractions from a cyanobacterial bloom, and the pure
compounds unnarmicin D and cannabidiol (CBD). Through these workflows, two new
anti-inflammatory metabolites have been discovered, a new opioid ligand has been
identified, and permeability coefficients for a common cosmeceutical have been
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evaluated. Early integration of these permeability methodologies will allow better preclinical outcomes for new drug candidates.
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CHAPTER 1: JUSTIFICATION OF RESEARCH
INTRODUCTION
Natural products continue to be the driving force in the discovery of new
small molecule therapeutics.1 Thousands of new molecules are discovered each year
providing an indispensable resource for new chemical diversity, including new agents
with previously undescribed mechanisms of action for quickly evolving diseases.2
Drug discovery from natural products often involves either an in-depth investigation of
the secondary metabolite arsenal of a single organism, or screening a library of
natural product extracts, fractions, or pure compounds against a therapeutic target.
Screening natural product libraries paired with efficient natural product workflows has
led to new therapeutics with novel mechanisms of action for diseases like cancer,
HIV, and bacterial infections.3-5 However, many natural product drug leads are
structural complex, which can result in unfavorable pharmacokinetic profiles. Poor
solubility, permeability, and stability of molecules is a common roadblock preventing
these metabolites from being developed into a drug, supplement, or cosmeceutical
product.5
There are a variety of methodologies that can be implemented to screen natural
product libraries. Screening crude natural product extracts requires little resources for
preparation but require large amounts of resources for purification and identification of
active metabolite. Pre-fractionated libraries can shorten the time to hit identification,
and pure compound libraries take many resources to produce, but hit identification is
rapid.6,7
Once an active metabolite has been identified through screening platforms, the
drug-likelihood of the compound needs to be evaluated. Many of the
pharmacokinetic and pharmacodynamic parameters will require in vivo analysis in
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animal models. However, if safety and efficacy testing is possible outside of an
animal model for early indications of drug-likelihood, such assays should be
prioritized. The lead compounds’ permeability through biologically relevant
membranes is important in determining if the compound will reach the target organ,
and how quickly it will reach the target. This information can then be used to
determine mode of administration and dosing regimen. In silico and in vitro
methodologies have been developed for early screening of permeability through the
skin, gut, blood brain barrier (BBB), and cells. Despite the current mechanisms to
increase permeability and bioavailability of lead compounds, early screening of druglikelihood using in vitro and in silico methods can eliminate weak drug candidates.
Drug permeability through biological membranes is integral in understanding and
assessing potential leads in the drug development pipeline. Many protein drug
targets of interest are located intracellularly; therefore, the compound must pass the
cell membrane and reach the cytosol to interact with the target. The rate of diffusion
will depend on the physiochemical parameters of the molecule, the characteristics of
the membrane of interest, active transport mechanisms, and the presence of efflux
pumps that may remove the compound once it has passed the membrane.8
There are several generalizations or “rules” that predict how likely a compound is
to become an orally bioavailable drug by comparing the relationship between
compound structure and common drug-like properties.9 Dr. Christopher Lipinkski’s
rule of 5, which considers a compounds molecular weight (MW), hydrogen bond
donors and acceptors, and hydrophobicity or logP is often used as the gold standard
of rules.10 However, this physiochemical analysis primarily focuses on the passive
nature of these molecules and in biological systems there are active transport
mechanisms that can allow a drug to reach the biological target.
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Natural products are biosynthesized within organisms and therefore resemble
endogenous ligands utilized in the physiochemical processes of other organisms.
This element allows more natural products to be actively transported across
membranes compared to synthetic alternatives.11 This attribute can be both
beneficial in the case of theophylline, a drug isolated from coca beans and used for
respiratory issues such as COPD which uses active transport mechanisms to pass
into the gut.12 Similarly, from a toxicokinetic perspective, transportation could be
harmful, cyanobacteria toxins of the microcystin family which are large relatively
hydrophilic peptides can accumulate in the liver and cause severe damage to
humans and animals. These molecules are transported by organic-anion transporting
polypeptides (OATPs) that are mainly expressed on hepatocytes and would not be
able to cause cellular damage without being actively transported into the cells.13 For
this reason, and others such as increased rigidity of natural compounds, natural
products do not always conform to Lipinski’s rules.14 Despite the discrepancy with
Lipinski’s rules and natural products, Quinn and colleagues found that 80% of natural
products had less than two violations to the developed rules, suggesting this is still a
valuable method for early evaluation of the structure-clinical drug relationship.9
A targeted approach to screening libraries can be taken by employing in vitro
permeability assays such as the parallel artificial membrane permeability assay
(PAMPA) and the Franz cell diffusion assay early in the developmental pipeline.15-17 In
silico methods using the physiochemical attributes of the compound and well
established “rules” of drug-likeliness can be utilized to predict potential
bioavailability.18-21 These methods can be applied to neuropharmacological drug
candidates as well as other compounds through biologically relevant membranes
such as the gut and the skin.
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There is a significant need to employ permeability analysis methodologies early
in the drug development pipeline, as well as the supplement and skincare industries
to produce targeted products with predictable biological responses. This dissertation
emphasizes the development of crucial methodologies for assessing and predicting
the permeability of natural products from crude extracts to pure compounds. Early
integration of these methodologies in drug development workflows will allow for better
pre-clinical outcomes for new drug candidate and have an important impact in drug
discovery and development.
The overall theme of this work is the pairing of unique natural product
screening libraries, constructed by myself and coworkers, with permeability assays
using biomimetic membrane systems for improved drug lead identification. In chapter
one of this dissertation, I will discuss the development of the Principle Rhode Island
Secondary Metabolite (PRISM) library and the subsequent screening of medicinal
plant extracts against various microbial pathogens. The latter part of this chapter will
also highlight the tulip tree (Liriodendron tulipifera); a plant that produces a unique
antibacterial compound that is effective against methicillin resistant Staphylococcus
aureus. Chapter two will expand the scope of screening to a library comprised of
cyanobacterial chromatography fractions, a rarified collection of microbial specialized
metabolites in comparison to a crude extract library. Two new metabolites in the
micropeptin family were identified through these workflows that reduce
neuroinflammation in BV2 microglial cells. The fourth chapter will discuss the pure
compounds Unnarmicin D, which was identified as a potential neurotherapeutic and
opioid receptor ligand through screening of a pure compound library comprised of
cyanobacterial metabolites from Trichodesmium thiebautii. The last chapter will
integrate new methods for studying the passive permeability of the Cannabis sativa
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metabolite cannabidiol, a metabolite from the Cannabis sativa plant through the skin
using multiple in vitro approaches.
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ABSTRACT
Chemical screening libraries often feature natural product extracts (NPEs) due to the
intriguing biological activities they possess, and the structural diversity found in their
individual components. A research project originally designed to create an extract library
of every specimen in the University of Rhode Island (URI) Heber W. Youngken Jr.
Medicinal Garden soon turned into a laboratory-based teaching project in which upperdivision undergraduate students generated and analyzed extracts in an academic minisemester project. Additionally, motivated upper-division undergraduates carried out
independent research isolating biologically active molecules. Hands-on laboratory
activities enhanced students’ knowledge of methodologies and workflows associated
with extract analysis and biological evaluation of botanical extracts. The synergy of the
laboratory course with the independent study contributed to workforce preparation and
library generation.

GRAPHICAL ABSTRACT
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Natural products comprise the majority of our pharmacopeia, with 73% of all new
approved drugs from 1981-2014 being natural products, natural product derivatives, or
drugs inspired by natural products.1 In the decade between 2000 and 2010, 38 natural
product-derived drugs were approved for use in various medical indications.2 Of the
more than 100 natural product-derived drugs in clinical development during this time
period, 91 were plant derived.2 The historical and cultural uses of natural products gives
herbal and botanical sources of new drugs somewhat of an advantage over unfamiliar
sources of natural products. Botanical-based discovery is frequently “experience driven”,
for instance an herbal treatment is associated with symptom alleviation, which is often
noted in traditional Chinese medicine (TCM) or ayurvedic medicine, which sets the stage
for the isolation and characterization of an active component. Herbal treatments include
whole plant extracts, mixtures of plant extracts, and the healing potential of functional
food.3 These multifunctional uses necessitate that analytical procedures improve quickly
to identify potential active components in extracts, and that diverse biological assays are
utilized to determine therapeutic potential. The paired desires to 1) create the Principle
Rhode Island Secondary Metabolite (PRISM) library from extracts of plants from the URI
Heber W. Youngken Jr. Medicinal Garden and 2) to provide upper-division

9

undergraduate students greater hands-on experience and research independence came
together to form the foundation of this educational and training experience. This
laboratory course enabled students to comprise our “workforce”, and to carry out
important procedures and workflows in natural product chemistry and medicinal
chemistry including HPLC (HPLC-UV), mass spectrometry (LC-MS), and biological
assays (DPPH antioxidant assay). At the end of the course and independent study,
students were better prepared for a career in the pharmaceutical sciences, and they
were excited to be part of a larger research project with a potential impact in drug
discovery.
RESEARCH QUESTIONS
We began this endeavor at the research laboratory level, asking ourselves if it was
feasible to generate an extract library of the greater than 200 specimens in the Heber W.
Youngken Jr. Medicinal Garden at URI. The goal was to create a collection of extracts
comprising the Principle Rhode Island Secondary Metabolite (PRISM) library, which
could then be used by internal and external partners as a chemical screening tool.
Additionally, a main goal was to acquire information on each extract including the
complexity of metabolite composition, the relative quantity of known medicinal
compounds, and biological activities of extracts. Furthermore, we wanted students to
modify and optimize chromatography methods during metabolic profiling. The process of
library construction, from harvesting and vouchering specimens, to generating extracts,
and acquiring biological and analytical information could be completed under the
umbrella of an upper-division undergraduate medicinal chemistry laboratory course. The
existing infrastructure of the medicinal chemistry course was easily altered to
accommodate a seven-week long research project dedicated to generating PRISM
library extracts and acquiring necessary analytical information on extracts. Students
gained experience in literature review, chromatography, spectroscopy, and spectrometry
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techniques in the pharmaceutical industry, and they were able to participate in a
research endeavor, which is presently continuing in an academic research laboratory.
Select highly motivated students continued to work on library construction via
independent study projects in which they completed bioassay-guided isolation to purify
plant metabolites.
METHODS AND FRAMEWORK
Two separate student cohorts participated: upper-division undergraduate students in
a laboratory course (teaching lab), and upper-division undergraduate students taking
part in an independent study project in an academic research laboratory (research lab).
The independent study project took place outside of the mini-semester course with
several students who had participated previously in the mini-semester engaged in
independent study. For the laboratory course, 46 students were introduced to the minisemester objectives and workflows in a lecture setting. These students were enrolled in
BPS 451, Techniques in Medicinal Chemistry and Molecular Biology, which is an upper
division undergraduate laboratory course in the Pharmaceutical Sciences major at the
University of Rhode Island. This course is a requirement in the Bachelor of Science in
Pharmaceutical Science major and students in the course have taken General and
Organic Chemistry as well as General Biology. The students have also taken more
specialized courses in pharmaceutical sciences such as Medicinal Chemistry,
Pharmaceutical Pharmacology, and Drug Metabolism and Bioanalysis. Students spend
six hours a week in the lab for the course in two three-hour blocks. Each day in the lab
began with a “pre-lab” component in which the concept of the PRISM library was
introduced and the theory of that week’s experiments were discussed in detail. When the
course moved into HPLC and mass spectrometry, we began a “post-lab” component in
which data were reviewed and new methods were developed. The post-lab was done as
an entire class with each group presenting their findings. This approach allowed for
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repetition and reinforcement of important ideas for each topic discussed. The students
were first assigned into groups of 3-4 students and each group harvested a plant
specimen from the garden. Preference was given to those plants that had not yet been
extracted, specimens prioritized for further study in the research lab, and plants that
were currently in bloom. Each botanical specimen selected for extraction and addition to
the PRISM library results in four extracts. Aerial and root portions are separated, and
each of those portions is divided in two. Aerial and root samples are extracted in both
organic (methanol) and aqueous (water) solvents. Thus, while the Youngken Garden
houses over 200 medicinal plants, the PRISM library will contain approximately 800
extracts. The approach in the teaching lab was to follow this framework. However,
certain specimens such as Aloe vera were not removed from the garden, and thus did
not have a root sample, and only aerial portions were analyzed. Specimens were dried
for one week and a portion of each specimen was placed in a voucher library housed in
the URI Herbarium. When specimens were ready for processing, each group was given
an ‘extract notebook’ sheet to complete, indicating important information on each
extraction. The sheets are housed in the laboratory of the corresponding author. A major
portion of the initial extract collected in the teaching lab was reserved for the PRISM
library (research lab). Each crude extract was placed into a vial in a barcoded Micronic
storage system, while 10 mg/mL solutions of each extract in DMSO were generated for
biological assays, and solutions were placed into 96-vial Micronic storage system. All
sample barcodes were entered into a database. In the teaching lab, students continued
with the remaining minor aliquot of extract for further teaching laboratory studies.
Throughout the remaining six weeks, students completed concentration of extracts in
vacuo, DPPH antioxidant assays on extracts, SPE fractionation, and additional DPPH
antioxidant assays using the SPE fractions. Fractions that possessed the strongest
antioxidant activity were further analyzed using HPLC-UV and LC-UV-MS. (Table 1).
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Data and results from these experiments are shown in the Supporting Information
document.

T1 1 Table 1. Topics covered by weeka

Week Topic

Techniques

Introduction to PRISM Library,
1

Laboratory Safety, Plant Harvesting

Voucher specimen preparation

& Vouchering
Extracting solids, filtration, rotary
2

Extraction & Concentration
evaporation

3

Bioassay & Chromatography

DPPH assay & SPE fractionation

Analytical Chromatography & Method
4

HPLC
Development

5

Metabolic Profiling

Mass spectrometry

6

Compound Identification

MS & NMR

Lab Presentation & Report
7

Scientific communication & writing
Preparation

a

Each week students contributed two 3 hour laboratory periods

Certain highly motivated upper-division undergraduate students were selected to
contribute to the PRISM library in an independent research setting. These students
continued to add extracts to PRISM, performed analytical procedures, and they
additionally completed bioassay-guided isolation projects to isolate and characterize
pure plant metabolites with anti-bacterial activity. These student groups made significant
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contributions to PRISM library construction and utilization (Figure S1) while practicing
key competencies for natural product chemistry workflows.
FINDINGS
The teaching lab class was divided into morning and afternoon sessions. There was
specimen overlap between the sessions, which validated the reproducibility of our
workflows, and ultimately led to seven additional extracts in the PRISM library.
Successful completion of the course entailed identifying an initial extract with the most
potent antioxidant activity (methanol vs. aqueous or aerial vs. root). As medicinal plants
contain many polyphenols and other organic compounds with antioxidant activity,4 each
group identified an extract with which to continue (Figure S2). The remainder of the
course was devoted to fractionating the active extract (SPE fractionation) and performing
bioassays on the more rarefied active subfractions (DPPH assay), optimizing HPLC
methods (HPLC-UV), and identifying putative metabolites responsible for the antioxidant
activity (LC-UV-MS). SPE fractionation afforded each group an active antioxidant
fraction (Figure S3), and while often subtle, groups were able to accomplish HPLC
method optimization to better resolve metabolite composition (Figure S4). The post-lab
portion of the class aided in students’ understanding of method optimization and it
ensured that each group received feedback from peers, teaching assistants, and the
instructor. The post-lab discussion additionally aids in filling laboratory time while
passive experiments such as MS acquisition take place. Student groups were able to
make at least one putative metabolite identification for components in five out of the
seven plant specimens (cf. Table 2 and Figure S5), and morning and afternoon groups
generally showed similar activity and metabolite profiles and made identical compound
identifications (Figure S6-S10). An example of the composition analysis on an aloe
methanol extract by LC-UV-MS is illustrated in Figure 1.
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T1 2 Table 2. Specimens analyzed and major compound(s) identifieda

Specimen

Common Name

Putative Compound
Identifications

Aloe vera

Aloe

Aloin A, Aloin B

St. John’s Wort

Quercetin, Isoquercetin

Comfrey

No putative identifications made

Hypericum
perforatum
Symphytum officinale

Japanese
Berberine

Berberis thumbergii
Barberry
Rosmarinus
Rosemary

Rosmarinic Acid

Humulus lupulus

Hops

Isoquercetin

Echinacea purpurea

Echinacea

No putative identifications made

officinalis

a

Analysis performed on single quadrupole MS system with polarity switching

enabled.

1

H NMR experiments were carried out on chromatography fractions in a previous

iteration of the course using a 300 MHz Bruker NMR spectrometer. We determined that
the complexity of NMR signals in sample mixtures posed too difficult an analytical
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experience for upper-division undergraduates. In the current course format, major
metabolites that are known to be produced by plants specimens and some of those
putatively identified from chromatography fractions were purchased from commercial
sources when available. Students analyzed these pure molecules via 1H NMR analysis
and assigned resonances to their structures.
Upper division undergraduate students in the research laboratory were instrumental
in development of the PRISM library. Each semester, one student focused their
independent research on producing extracts from the garden. These students generated
an average of 30 extracts per research semester. Other students in the research
laboratory focused on harvesting and vouchering plants specimens, and generated five
extracts on average per semester. These students were able to cross-train each other
on matters concerning the routine procedures in generating the extract library. Additional
questions were sent to the graduate student on the project or the faculty mentor. During
bioassay research in the laboratory, although there are limitations with undergraduates
working with pathogens (methicillin-resistant Staphylococcus aureus, MRSA), the
students were instrumental in fractionating extracts of interest. For separations, students
used flash chromatography and time-based semi-preparative HPLC collections. After
this rarefication procedure, they assisted with HPLC and MS analysis of the fraction of
interest, and assisted with dereplication. This resulted in the isolation of several pure
plant metabolites, which showed potent anti-MRSA activity. These results will be more
elaborately discussed in a future research article

LIMITATIONS
While the course overall was deemed a success based on the bioassay and mass
spectrometry results, there are improvements we plan to implement in future iterations of
the course. The first is a course expansion beyond seven weeks. This will allow more
hands-on experience with HPLC and mass spectrometry. Future experiments can be
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designed to compare metabolites between plant parts (aerial vs. roots), or to focus on a
distinct group of medicinal plants (ex. Euphorbia species). Additionally, mass
spectrometry experiments will be designed for implementation earlier in the course. It is
possible that the groups studying echinacea and comfrey would have identified major
metabolites in whole extracts, when they were not able to do so from rarefied
chromatography fractions with fewer metabolites present than those found in crude
extracts. The URI College of Pharmacy is fortunate to have a world-renowned medicinal
garden, an experienced garden coordinator, and an exceptional teaching laboratory with
four HPLC-UV systems and two LC-UV-MS systems for analysis. This infrastructure
affords a course framework with many opportunities for hands-on learning by students.
However, the framework of the course can be easily modified for teaching labs with
fewer analytical instruments and for those lacking a plant garden. Herbal and botanical
samples can be purchased or collected. University herbariums can be a resource for
specimens and pending a permit, collections can often be carried out in public lands.
Additionally, there are commercial sources for ornamental and medicinal seeds. Many
common weeds and invasive plants contain unique and understudied metabolites.5,6
Specimen libraries can be created from terrestrial or aquatic plants, bacteria, and fungi,
which would also incorporate important cultivation techniques. A focus on
chromatography and spectrometry can shift to bioassays, which are generally
inexpensive, high throughput, and informative. While there are limitations, a minisemester course of experiments building towards a final report has distinct advantages
over a laboratory course consisting of disparate weekly endeavors. The mini-semester
promotes integration, project ownership, and the development of background knowledge
that mirrors the skills needed to excel in pharmaceutical industry positions, and to
enhance workforce development. Rather than learning each skill separately, students
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are able to integrate a variety of analytical techniques to ultimately build a metabolic
profile for a plant that grows in the Heber W. Youngken Jr. Garden.
IMPLICATIONS
Incorporating laboratory classes and independent study into the generation of the
PRISM library had several positive outcomes for students in the teaching lab:
1. Students experienced “buy-in” by contributing to a research project that extended
beyond the course itself.
2. Introduction to integrative and multidisciplinary approaches in analytical chemistry
and biology in a discovery context.
3. Introduction to the concept of de-replication (limiting compound re-discovery) with
respect to natural product chemistry research.
4. Enhancing the ability to communicate and write scientifically by completing
presentations and laboratory reports.
5. Replacing the concepts of being “right or wrong” with a more nuanced approach,
which mimics academia and industrial project workflows.
Additional outcomes for advanced students in the research lab:
1. Exposure to more complicated workflows under supervision.
2. Continued project when laboratory courses were not in session.
3. Leadership development through near-peer mentoring, as experienced
undergraduate students train and assist new students under the direction of both a
graduate student and faculty mentor.
4. Scholarly development by contributing to journal articles, and gaining experience in
manuscript preparation and submission during their undergraduate studies.

While the corresponding author has been an instructor in BPS 451 since 2016,
specimens from the medicinal garden were not introduced until 2018. In 2018, the
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course began to evolve into the mini-semester project in which student groups focused
on acquiring analytical information on one plant specimen from the garden. The creation
of the PRISM library began in 2019 and its integration into the course framework is the
subject of the current report. We do think that the mini-semester project concept and the
increased focus on active and collaborative learning has led to better student learning
outcomes. However, we plan to include more targeted assessment questionnaires in
future iterations of the course, which will explore the impact of this course on student
learning, such as learning specific skills in spectrometry and spectroscopy. With respect
to independent study students in the research laboratory, we will gauge student
outcomes based on participation as authors in research articles and presentations as
well as employment in industry or graduate school. While this approach to a laboratory
mini-semester was inspired by other teaching laboratories published by this journal,7-9
there are significant departures from previously published work. This teaching laboratory
is paired with independent study, which incorporates and accelerates inquiry-based
learning, personalized learning, and peer-to-peer mentoring. The deliverables from this
course transfer directly to the academic research laboratory setting. Furthermore, the
incorporation of mass spectrometry in the teaching laboratory is highly relevant to
pharmaceutical scientist training in areas such as structure characterization,10
composition analysis,11 metabolomics,12 and quantitative analysis.13 These skills are in
demand in the pharmaceutical industry and future plans include expanding the LC-MS
component by the incorporating LC-MS/MS analysis into the course.
HAZARDS AND SAFETY PRECAUTIONS
Students were given a laboratory safety lesson and a laboratory tour before the first
experiments were
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carried out. Eye washes, safety showers, spill kits, and appropriate hazardous waste
disposal areas
were identified. Students also researched any toxic substances produced by their
specimens.
Supporting Information (Appendix A)
The Supporting Information is available on the ACS Publications website at DOI:
10.1021/acs.jchemed.
Supplemental Figures and Data (DOCX)
Additional Experimental Details (DOCX)
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ABSTRACT
Pathogenic bacteria continue to pose threats to human health, and cost billions
of dollars in healthcare annually. Two of the most common bacterial infections are
urinary tract infections (UTI) caused by Escherichia coli, and Staphylococcus aureus
infections. Some strains of S. aureus have become resistant to common antibiotics, and
there is a critical unmet need for the discovery and development of new drugs. The
discovery of new small molecules that can eradicate a UTI fully, including cells in a
quiescent stage is also needed to prevent reoccurring infections. Medicinal plants have
shown promise as sources of new small molecule therapeutics and supplements. The
PRISM library, described in the previous chapter, was screened for activity against
strains of methicillin-resistant S. aureus (MRSA) and uropathogenic E.coli. A
sesquiterpene lactone (laurenobiolide) from the tulip tree (Liriodendron tulipifera) was
identified as the active component from the tulip tree extract against S. aureus and a
metabolite from saffron (Crocus sativus) was identified for activity in reversing E. coli
quiescence.

INTRODUCTION
Infections caused by pathogenic bacteria claim millions of lives yearly and accrue
billions of dollars in healthcare costs.1 The discovery and implementation of antibiotics to
combat pathogens has saved millions of lives worldwide since the discovery of penicillin
by Sir Alexander Fleming in 1928.2,3 The penicillin molecule contains a β-lactam ring that
acts as the warhead killing bacterial cells by inhibiting the formation of cell walls.4 Only
decades after Fleming first introduced penicillin to the world, the bacteria that were once
killed by penicillin began to develop resistance to the molecule, and subsequent
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antibiotics such as methicillin, which also contains a β-lactam ring. Apart from β-lactam
antibiotics, various other classes of antibiotic molecules that have unique mechanisms of
action such as inhibiting protein biosynthesis, inhibiting DNA synthesis, or inhibiting
metabolism of folic acid have been discovered and utilized in the clinic.4 However,
bacterial resistance continues to develop to new chemical entities.
One persistent pathogen is methicillin-resistant Staphylococcus aureus (MRSA).
MRSA is an economically important pathogen associated with morbidity, mortality, and
extended hospital stays. MRSA can infect multiple human organs, but the skin is the
most common. Untreated MRSA infections can lead to invasive infections that lead to life
threatening conditions such as endocarditis.5 Cases of endocarditis are increasingly
prevalent in illicit drug users from actions associated with injection drug use such as
failure to clean needles or hands before use.6
Beyond developing resistance to antibiotics, some bacteria develop alternative
ways to persist despite the introduction of drugs designed to eradicate them. One
persistent pathogen is uropathogenic Escherichia coli (UPEC). UPEC infections are the
most common type of bacterial infection and are responsible for 65-90% of UTIs.7 In the
United States alone, this accounts for nearly $5 billion dollars in healthcare costs
annually.8 Even after the UTI is initially treated, 20-30% of adult women will have a
recurring UTI emerge within 4 months.9 Interestingly, in 77% of UTIs, it is the original
bacterial strain that is responsible for the recurrence.7 This is possibly due to the E. coli
developing a biofilm-like intracellular bacterial community (IBC) and quiescent
intracellular reservoirs.10 These adaptations allow the E. coli to enter a quiescent state
where the bacteria hide in the epithelium of the bladder, evade antibiotic molecules, and
then periodically re-emerge and re-colonize to facilitate a UTI.11
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Antibiotic drugs typically target components of actively dividing bacteria, allowing
the E. coli in the quiescent state to avoid eradication.12 Some natural products such as
components in cranberry (Vaccinium macrocarpon) have shown efficacy in interfering
with bacterial adherence to bladder cells, which can help reduce E. coli populations in
cells. A novel assay developed at the University of Rhode Island utilizes glucose minimal
media paired with low density E. coli on agar plates, allowing the cells to exhibit
quiescence, but stimulation via small molecules can reverse this phase and generate
observable colonies.7
Plant metabolites offer promise in providing new molecular scaffolds to use as
antibiotics either alone or in combination with previously discovered antibiotics to
increase the efficacy.13,14 The same metabolites that the plant uses to fight microbes in
the environment can be harnessed to combat human pathogens.
The University of Rhode Island houses a medicinal garden comprised of over
200 specimens. Recently, we developed a new plant extract library comprised of
aqueous and organic extracts of aerial and root portions of each specimen from the
garden.15 The extract library was utilized in anti-bacterial testing using a strain of MRSA
and uropathogenic E. coli strain.
Herein, we identified the methanol extract of the tulip tree (Liriodendron
tulipifera) as having activity against a MRSA strain. This extract was investigated further
through bioassay-guided isolation. The active compound was ultimately identified as
laurenobiolide, a sesquiterpene lactone. We further investigated the relative abundance
of this compound in the various parts of the plant. Lastly, we determine the safety of this
compound to human skin cells, as well as the isolated congeners of laurenobiolide tulipinolide and epi-tulipinolide. The methanol extract of saffron (Crocus sativus) was
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highlighted as one of the many extracts able to reverse E. coli quiescence, which was
also subjected to bioassay-guided fractionation and isolation.

RESULTS AND DISCUSSION
Although numerous plant extracts showed activity in these assays, the plant
extracts that were prioritized for the S. aureus and UPEC work included plants that had
been understudied in the literature, and plants with traditional uses relevant to the work
(e.g. tulip tree and saffron).
Liriodendron tulipifera or the tulip tree, is a large flowering deciduous tree found
naturally across the eastern side of the United States. Native American tribes used the
tulip tree for its valuable wood, but medicinally it was utilized as a tonic, antipyretic, and
it was used to treat malaria.16-18 Early American settlers used this native knowledge and
utilized the bark of the tulip tree as a replacement for Cinchona bark for anti-malarial
activity.17 During the Civil war, the botanist and surgeon Francis Porcher was tasked with
compiling a book containing plant remedies that are native to the Southern States to aid
in helping soldiers deal with injuries. One of the plants he highlighted in his short book
was the tulip tree.19,20 As research and development grew and scientists began to study
traditional medicine, some of the original uses of the tulip tree were validated. Once such
validation was discovering the anti-plasmodial activity of the aporphine alkaloids and
sesquiterpene lactones isolated from the tree.21
There has been a consistent effort to develop drugs with unique chemical
structures and mechanisms of action to combat pathogen resistance.22 Compared to the
other common classes of antibiotics such as β-lactams, cephalosporins, and
tetracyclines, there are very few anti-bacterial compounds in the terpene class.
However, terpenes and terpenoids are an incredibly diverse group of phytochemicals
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that show potential as potent antimicrobials.23 The exact mechanism of action of terpene
antibiotics is unknown, but Griffin et al. identified that terpene metabolites inhibit two
essential processes, which include oxygen uptake and oxidative phosphorylation.24
Initial screening of the tulip tree methanol extract via antimicrobial disc diffusion
assay showed moderate activity against methicillin-resistant S. aureus. Upon
investigation of the metabolite profile via high performance liquid chromatography
(HPLC) (Figure S1), the complex extract was further fractionated and re-tested in the
MRSA assay. Five fractions of varying polarity were tested and the most activity was
observed from fractions 3 and 4 corresponding to a 40% water: 60% methanol fraction,
and a 20% water: 80% methanol fraction, respectively (Figure 1). Upon visual analysis
of the HPLC chromatograms for each fraction, the most active fractions contained two
large peaks eluting at 30 minutes from the column. It was speculated that a compound in
one of these peaks could be responsible for the observed activity.

F1 1 Figure 1: Antibacterial activity of L. tulipifera chromatography fractions on
methicillin-resistant S. aureus. Samples were prepared at 1 mg/mL. Zones of inhibition
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were evaluated after 24 h after incubation at 37°C. Controls were (+) gentamicin sulfate
and (-) methanol.
Following this examination, the two prominent peaks were isolated via HPLC and
retested for MRSA growth inhibition. The later eluting peak exhibited the largest zone of
inhibition (Figure S2A). The peak purity was checked using a phenyl-hexyl column and it
was determined that the earlier eluting peak (peak 1) was a single pure compound.
However, the later eluting peak (peak 2) was two separate compounds (Figure S2B).
Upon repurification and retesting of the three compounds, it was determined that only
peak 2.1 had antimicrobial activity. Peaks 1 and 2.2 did not show any observable
activity. Upon dereplication via 1D and 2D NMR (Figure S3 – S6) and HRESIMS (Figure
S7) it was determined that the three compounds were isomers. The active peak 2.1 was
determined to be laurenobiolide by the specific rotation [α]23D 16.8 (c 1.0, EtOH) which
closely matched the literature value of [α]25D 17.1 (EtOH) for laurenobiolide.25
Additionally, examination of the 1H NMR spectra of peak 2.1 showed an envelope of
olefinic protons from δ 4.70 to 5.50 consistent with the original characterization of this
metabolite,26 and the 1H NMR spectrum clearly showed the presence of conformational
isomers, a phenomenon previously described for laurenobiolide during NMR analysis. 27
Examination of 1H NMR spectra identified peak 1 as epi-tulipinolide, and peak 2.2 as
tulipinolide. Evidence included a multiplet resonance at δ 5.72 in peak 1 corresponding
to H-8, which was in a cluster of resonances between δ 4.76 and 5.03 in peak 2.2.
Furthermore, the acetyl methyl groups at δ 2.09 and 2.06 were consistent with those of
tulipinolide and epi-tulipinolide, respectively as detailed in the original isolation and
elucidation work as were the olefinic methyl groups.28 Interestingly, among these three
sesquiterpene lactones that are extremely similar in structure (Figure 2), only
laurenobiolide displayed antibiotic activity towards S. aureus.
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F1 2 Figure 2: The active compound was determined to be the sesquiterpene lactone
laurenobiolide. The other inactive congeners were identified as tulipinolide and epitulipinolide.

The minimum inhibitory concentration (MIC) for laurenobiolide was determined to
be 15 µg via broth dilution assay. The tulip tree has documented antimicrobial activity
but the molecule responsible for the activity had not been identified until now.18 Lastly,
the three sesquiterpene lactones were evaluated for their cytotoxic effects to human skin
cells (Figure 3). An IC50 value of 17.4 µM was measured for laurenobiolide, 49 µM for
epi-tulipinolide, and 65.3 µM for tulipinolide. Further evaluation via animal studies will be
necessary to develop a full cytotoxicity profile.
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F1 3 Figure 3: Cytotoxicity of isolated compounds from the L. tulipifera tree on human
keratinocyte skin cells (n=3).

Lastly, we investigated which parts of the tulip tree contained the highest
concentrations of the active compound. On the day of collection, the plant was not in
bloom, so the flowers were not evaluated, however, previous analysis does indicate that
laurenobiolide is present in the flowers (Figure S8). Molecular networking analysis was
performed to evaluate the remaining parts consisting of the bark, petiole, leaves, and
branches. Examining HPLC-DAD data, laurenobiolide was most abundant in the
branches, and it was also present in the leaves and flowers although in smaller quantities.
Small quantities were observed in the petioles following HPLC-DAD analysis, but the
active component was not detected from this part following LC-MS/MS analysis.
Interestingly, laurenobiolide was not detected in the bark in either analytical approach
(Figure 4). This is consistent with the traditional Native American uses of the branches for
medicine, and these data will now inform future harvesting of plant parts while provoking
intriguing questions about the ecological role of this metabolite for the tree.
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F1 4 Figure 4: Molecular networking analysis of the tulip tree showing the active
antimicrobial compound laurenobiolide in the branches (green) and the leaves (red).
This compound was not detected in other parts of the tree such as the petioles (blue)
and the bark (orange). Cosine scores are shown in blue, and the size of the node is
relative to the ion count.

Turning to UPEC, the quiescence reversing activity of 114 plant extracts was next
evaluated. After the initial testing of the crude extracts, 79 of the 114 (69.3%) showed
some observable activity and the remaining 35 extracts (30.7%) showed no observable
activity. Out of the 79 extracts that were active we prioritized pursuing extracts that 1) had
the largest zone of activation 2) were organic extracts and 3) activity was only observed
for methanol extracts (aqueous extract was inactive). The reason for prioritizing organic
extracts stems from previous research with quiescence reversing molecules. We know
that amino acids such as lysine and methionine have shown activity as well as sugar
molecules like those in the cranberry plant, which would be extracted in an aqueous
solvent.7 One extract stood out because of its agricultural and economic impact and that
was the petal extract of the Crocus sativus plant, or saffron, a plant widely known for its
medicinal and culinary uses.29 The stigmas of saffron are collected, dried, and sold as the
world’s most expensive spice, but the remainder of the plant is often discarded as
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agricultural waste.26 Therefore, observed activity in the petals is desirable because the
plant is already extensively cultivated and access to biomaterial is widely available.
Samples 94-99 (Figure S9) corresponded to the saffron samples, and the 20%
water: 80% methanol fraction was prioritized for bioassay-guided isolation due to the
large zone of activation. Time-based fraction collection was used to separate this active
sample into metabolite pools for retesting (Figure S10). Fraction pool 1 showed the most
quiescence reversing activity, and a new HPLC method was developed to isolate the
compounds in pool 1 and retest in the assay (Figure S11). Compounds 4 and 5 showed
the most activity (Figure S12, but upon dose titration, compound 4 showed the most
potent activity (Figure S13). Efforts have been made to dereplicate the active compound,
including fragmentation of the active compound via HRESIMS/MS (Figure S14), in which
a neutral loss was observed of 162 Da (Figure S15), and the observed M+H was 319.
These data paired with the 1H NMR spectrum of the active compound (Figure S16)
indicated the presence of a sugar moiety. Further evaluation using mass spectrometry
and 2D NMR experiments will be needed for full structure elucidation of this compound.
In this report, we have documented for the first time that the natural product
laurenobiolide possesses potent anti-MRSA activity, which sheds light on the intriguing
story of the cultural and historical use of tulip tree preparations. Furthermore, we have
shown the utility of the PRISM library as a source of molecular potential in a variety of
therapeutic areas. Future research will focus on the mechanism of action of
laurenobiolide, its ecological role for the tree, and we will continue to elucidate the
structure of the active quiescent-reversing component and search for other lead
metabolites with this biological activity.
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MATERIALS AND METHODS
General Experimental Procedures. Optical rotations were measured using a Jasco P2000 polarimeter. NMR spectra were recorded using a Varian 500 MHz instrument.
HRESIMS analysis was performed using an AB SCIEX TripleTOF 4600 mass
spectrometer with Analyst software. MS/MS data were recorded on this same instrument
using the product ion function. LC-MS/MS was performed using a ThermoFisher LTQ XL
mass spectrometer with an electrospray ionization (ESI) source. Semi-preparative and
analytical HPLC was carried out using a Dionex UltiMate 3000 HPLC system equipped
with a micro vacuum degasser, an autosampler, and a diode-array detector.
Preparation of plant extracts
Plant extracts were prepared as previously described.15 Briefly, plants were separated
into aerial and underground portions, then further divided for extraction in both aqueous
and organic (methanol) solvents. Each solvent was vacuum filtered to remove
particulates, then either freeze-dried or evaporated under reduced pressure to remove
any remaining solvent. Dried product was sub-aliquoted into small vials and
reconstituted at 10 mg/mL in (CH3)2SO.
Bacterial strains and cultivation
The E. coli strain CFT073 was obtained from the laboratory of Dr. Jodi Camberg, from a
cryogenically preserved frozen stock comprised of a 1:1 combination of LB broth and
50% glycerol. For E. coli cultivation, both LB broth and LB agar were routinely used.
Liquid M9 media was used in a method developed by Dr. Paul Cohen and the M9 agar
plates were prepared with 1.5% noble agar.30
In vitro quiescence inhibition assay
The methods used in the quiescence inhibition assay follow Dr. Paul Cohen’s methods
as described in Leatham-Jensen et. al. 2016.30 Briefly, cultures of E. coli CFT073 were
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grown overnight in 0.4% glucose with M9 minimal medium. The E. coli were further
diluted to a final concentration of 205 CFU in 4 mL of liquid overlay media. 0.2% glucose
M9 minimal media agar plates were prewarmed and the 4 mL of overlay inoculum was
poured over the agar then allowed to solidify at room temperature. Plant extracts
reconstituted at 10 mg/mL were spotted onto the plates with 10 μL of each test solution.
The E. coli that were not growing were considered to be quiescent if the growth was able
to be induced by the positive control consisting of 5 μL co-spotted tyrosine, lysine, and
methionine at 0.1 mg/mL. A positive result was defined in this assay as visually
observable bacteria growth at the spot of testing after a 24 h incubation. Negative results
were defined as no observable growth at the test site after 24 h. Images of each agar
plate were taken using a Molecular Imager Gel Doc XR+ (Bio-rad, Hercules, CA, USA)
system with Image Lab Software.
Methicillin-resistant Staphylococcus aureus inhibition assay
Liquid LB broth (Difco, Fisher scientific, Waltham, MA) was autoclaved in 10 mL aliquots
in capped culture tubes. Methicillin-resistant Staphylococcus aureus strain DSM 1104 (a
gift from Dr. David Rowley’s laboratory at URI) was kept in the -80°C freezer until
inoculation, and then a sterile loop was used to transfer bacteria to growth broth.
Samples were grown overnight at 37°C. LB agar (Alpha biosciences, Baltimore, MD)
was autoclaved, and 15 mL was poured into 100 x15 mm petri dishes (Thermo fisher,
Waltham, Ma). Agar plates were left at room temperature to solidify. After drying, the
plant extracts were prepared as described above and 20 μL were placed on a sterile
antimicrobial susceptibility test disc (Oxoid, Thermo Fisher, Franklin, MA), and allowed
to dry for 30 minutes. The positive control, gentamicin sulfate was prepared at 2 mg/mL
and 10 μL was added to a disc for each plate. Negative vehicle controls were (CH3)2SO
or CH3OH (20 μL).
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Minimum inhibitory concentration (MIC) of tulip compounds
The minimum inhibitory concentration of laurenobiolide was evaluated using a
broth dilution method. The MRSA was grown overnight in a 10 mL culture tube
consisting of sterile LB broth. A 1:1000 dilution was completed by taking 100 µL of
culture and placing it into 9.9 mL of fresh LB media and vortexing to mix. This mixture
was further diluted 1:10 by taking 1 mL of the first dilution into 9 mL of new LB broth. A
96-well round bottom plate (Corning, Corning, NY) was labeled with samples in triplicate
with positive and negative controls being gentamicin sulfate and methanol). 195 µL of
diluted bacteria was pipetted into the first row of the 96-well plate. 100 µL was added to
each row following. 5 µL of the test samples and controls were added to the first row of
the corresponding wells. Samples were mixed and serial diluted by taking 100 µL of the
first row, mixing with 100 µL in the following and continuing until the last row where the
final 100 µL was discarded. The plate was covered with a breathable cellulose
membrane and incubated for 24 h. Following incubation, bacterial growth was assessed
by measuring OD600.
Bioassay Guided Fractionation of Crude Plant Extracts
Prioritized extracts were further fractionated to rarify samples before additional testing
using C18 SPE cartridges (Agilent, Lexington, MA). Five fractions were produced from
each crude extract, beginning with the most polar (80% H2O: 20% CH3OH) and ending
with the least polar (100% CH3OH). Following solvent removal, the chromatography
fractions were reconstituted at 10 mg/mL in mobile phase followed by HPLC analysis. A
70 min gradient was utilized beginning with 15% acetonitrile (CH3CN) for 10 min, then
increasing the concentration of CH3CN until 45 min, with a 20 min hold at 100% CH3CN,
followed by a return to starting conditions for 5 min. The resultant chromatograms were
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visually evaluated in parallel with repeated antimicrobial assays to identify potential
active compounds.
Culturing Human Keratinocytes (HaCaT)
Human keratinocytes (HaCaT) were a kind gift from the laboratory of Dr.
Navindra Seeram at URI, and originally purchased from American Type Cell Culture
Collection (ATCC, Rockville, USA). The culture was maintained in Dulbecco’s modified
Eagle’s medium (DMEM) (Life Technologies, Gaithersburg, MD, USA) and the DMEM
was supplemented with 10% fetal bovine serum (FBS, Life technologies). The incubator
was kept at 37°C with 5% CO2 at constant humidity. All test samples were dissolved in
sterile (CH3)2SO for viability assessments.
Cytotoxic evaluation of keratinocytes (HaCaT) in the presence of L. tulipera
compounds
The viability of HaCaT cells in the presence of laurenobiolide, tulipinolide, and
epi-tulipinolide was evaluated using cell titer glo (CTG 2.0). HaCaT cells were seeded in
a sterile 96-well plate at 5x103 cells per well and incubated for 12 h, which was the time
necessary for adherence. Following this incubation, media was removed from each well
and compounds were added along with new media, followed by a 24 h incubation. After
the allotted time, the CTG 2.0 reagent was added to each well and shaken at 200 rpm
for 2 min using an orbital shaker. The plate was allowed to equilibrate at room
temperature for 10 min, and then the luminescence was recorded using a Spectramax
M2 plate reader.
Isolation of sesquiterpene lactones from Liriodendron tulipifera
Having identified the potential active components in the chromatography
fractions following initial chromatogram analysis, fractions 3 and 4 were combined and
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subjected to reversed-phase semi-preparative HPLC using a Kinetex 5 μm C18 column
(250 x 10 mm) and a gradient method. Mobile phase: 60% CH3CN /40% H2O with 0.05%
formic acid added to each solvent and flow rate of 3 mL/min. Initial conditions were held
for 10.5 min followed by a linear gradient to 12 min reaching 100% CH3CN and holding
at this concentration for 4 min, ultimately returning to initial conditions from min 17-20.
Two chromatographic peaks were collected at tR 9.5 (peak 1 - epi-tulipinolide) and 10.0
min (peak 2), respectively. Peak 2 was further purified using a Phenylhexyl 5 μm C18
column (250 x 10 mm) and an isocratic method. Mobile phase: 55% CH3CN/45% H2O
with 0.05% formic acid added to each solvent and flow rate of 3 mL/min. Peaks 2.1
(laurenobiolide; tR 13.5 min) and 2.2 (tulipinolide; tR 14.25 min) were isolated. The
specific rotation measured [α]23D 16.8 (c 1, EtOH) closely matched the literature value of
17.1 (c 1, EtOH) for laurenobiolide.31
Molecular network analysis of L. tulipifera plant parts
Samples of tulip tree bark (trunk bark), branch, petiole, and leaf were taken from
the specimen on the URI campus and methanol extracts were made as previously
described. Each extract was subjected to LC-MS/MS analysis with a specific scan event
recording MS/MS spectra in data-dependent acquisition mode. A Kinetex 5 μm C18
column (150 x 4.6 mm) was used for separation of analytes in the extracts. The LC
method consisted of a linear gradient from 15% to 100% CH3CN in H2O + 0.1% formic
acid over 20 min, followed by an isocratic period at 100% CH3CN of 5 min. The flow rate
was held constant at 0.4 mL/min. The MS spray voltage was 3.5 kV with a capillary
temperature of 325 °C. For the MS/MS component, the CID isolation width was 1.0 and
the collision energy was 35.0 eV. Following acquisition, the raw data files were
converted to mzXML format using MSConvert from the ProteoWizard suite
(http://proteowizard.sourceforge.net/tools.shtml). The molecular network was generated
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using the online platform at Global Natural Products Social Molecular Networking
website (gnps.ucsd.edu). A network was then created where edges were filtered to have
a cosine score above 0.7 and 6 matched peaks. The network was visualized using the
Browser Network Visualizer tool available on the gnps website.32
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ABSTRACT
Metabolite mining of environmentally collected aquatic and marine microbiomes offers a
platform for the discovery of new therapeutic lead molecules. Combining a prefractionated chromatography library with LC-MS/MS-based molecular networking, and
biological assays, we isolated and characterized two new micropeptins (1 and 2) along
with the previously characterized micropeptin 996. These metabolites showed potency in
anti-neuroinflammatory assays using BV-2 mouse microglial cells, showing 50% reduction
in inflammation in a range from 1-10 μM. These results show promise for cyanobacterial
peptides in the therapeutic realm apart from their impact in environmental health and
provide another example of the utility of large pre-fractionated natural product libraries for
therapeutic hit and lead identification.
INTRODUCTION
Neuropathic pain, or nerve pain, resulting from damage to or dysfunction of the
somatosensory nervous system is notoriously difficult to treat. Neuroinflammation is key
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in the initiation and persistence of neuropathic pain.1 Recent research has shown that the
prevalence of neuropathic pain in the United States is approximately 10% of adults, and
out of those reporting neuropathic pain over 40% were treating with either weak or strong
opioid drugs.2 This prevalence of neuropathic pain increases in specific cohorts with 33%
of those with chronic back pain displaying characteristic signs of neuropathic pain.3
Additionally,

chronic, uncontrolled neuroinflammation

is

an indicative

sign of

neurodegenerative diseases such as Alzheimer’s Disease and Parkinson’s Disease.4,5
Our group is interested in the discovery of new specialized metabolites from marine and
aquatic microbiomes that are effective in reducing neuroinflammation. While we have had
some success in this approach by mining marine cyanobacterial blooms for antineuroinflammatory agents,6 freshwater cyanobacterial blooms offer additional chemical
space for discovery, especially in terms of cyclic peptides.7 These peptides belong to
several classes including the microcystins, aeruginosins, microginins, anabaenopeptins,
micropeptins, microviridins and cyclamides. More than 600 peptides and peptidic
compounds have been described from various cyanobacterial taxa.7 Many of these
peptides are hepatotoxic, such as the microcystins, which can cause non-alcoholic liver
disease and acute liver failure.8,9 Consumption of contaminated drinking water is
considered the major route of human exposure to microcystins, and the EPA has set
concentration limits on these toxins (1.6 μg/L = Do Not Drink; 20 μg/L = Do Not Use).
While neurotoxins and hepatotoxins are a significant public health concern, these blooms
are comprised of a complex milieu of taxonomically diverse microbes, each possessing
various biosynthetic capabilities. Large scale biomass sampling from groups like Biosortia
have revealed freshwater cyanobacterial blooms are more chemically complex than
previously assumed, and novel molecules with potent biological activities can be isolated
and characterized.10,11 Work on this ‘metabolite mining’ from complex aquatic microbiomes
envisions the bloom environment as an ecosystem level complex co-culture experiment
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in which the aquatic microbiome is producing an equally complex suite of secondary
metabolites.
The use of prefractionated natural product libraries has shown promise in increasing
the potential of identifying lead structures following a bioassay-guided discovery
approach.12 Biosortia Pharmaceuticals has generated a prefractionated library from
cyanobacterial biomass dominated by Microcystis aeruginosa originally isolated from a
wastewater management facility in Muskegon, Michigan. Previous mining of this material
resulted in the isolation and structure elucidation of new highly cytotoxic microcystin
toxins.10 A similar workflow was implemented for biomass collected from Grand Lake St.
Mary’s in Ohio, and this effort resulted in the identification and characterization of the
exquisitely potent cyanobufalin toxins.11 Each chromatography fraction in the library
contained a rarefied mixture of chemicals allowing hits to be identified from less complex
starting material compared to crude extracts or more complex fractions. Pairing the
prefractionated library with metabolite profiling tools such as LC-MS/MS-based molecular
networking afforded the opportunity for rapid annotation and dereplication.13 Implementing
these approaches allowed our group to isolate and characterize two new micropeptins (1
and 2) and the previously discovered micropeptin 996 (Figures 1 and S1). All three
metabolites showed potent inhibition of the inflammatory response in BV-2 murine
microglial cells.

F2 1

Figure 1. Structures of micropeptins 982 (1) and 957 (2).
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RESULTS AND DISCUSSION
Structure Elucidation of Micropeptin 996, 1 and 2.
Biosortia’s chromatography fraction library consisted of over 150 individual samples
each with a rarefied collection of microbial metabolites. Following a bioassay-guided
isolation approach, we prioritized fractions with low cytotoxicity and strong antiinflammatory effects in the BV-2 murine microglial cell line. Fraction D29 showed no
significant cytotoxicity and inhibited the production of nitric oxide species (NOS) in the
cells by greater than 50% at a 10 μg/mL dose (Figures S2 and S3).
While we were using a pre-fractionated library for screening, the samples were
still relatively complex, likely due to the complex consortia of bacteria and other
microbes in the original biomass. In order to rapidly annotate and visualize the chemical
space in the fraction of interest (D29), we subjected the fraction to LC-MS/MS analysis
followed by molecular networking. The resultant network showed five separate clusters
with clusters 1 and 2 showing 15 and 9 individual nodes, respectively and parent
masses between m/z 900-1100 (Figure S4). Comparing precursor m/z values and
previous molecular networks available in the literature, we putatively identified the
metabolites in clusters 1 and 2 as micropeptins or cyanopeptolins.14,15 Nodes 1019 and
1005 showed high ion counts in mass spectrometry analysis and were abundant in the
HPLC chromatogram and these metabolites were targeted for isolation (cf. Figure 2, S4,
and S5).
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F2 2

Figure 2. Molecular networking cluster showing micropeptin 982 (1) and micropeptin

996 as nodes 1005 (M+Na+) and 1019 (M+Na+), respectively. These nodes are enlarged
and in yellow.

Following examination of the molecular networks, additional chromatographic
procedures and testing led to the isolation of three metabolites (Figures S5 and S6). 1H
NMR and 13C NMR analysis indicated that these molecules were peptidic in nature and
that they were closely related to each other in chemical structure (cf. Figures S7, S8,
S11, S12, and S20).
The first metabolite of interest (Fraction D29, peak 7) gave an m/z of 1019.4854
[M+Na]+ following HRESIMS analysis suggesting a molecular formula of C52H68N8O12
(Figure S9). Dereplication efforts based on mass spectrometry data (Figures S9 and
S10) identified micropeptin 996 as the likely metabolite and further examination of 1H
NMR and 13C NMR spectra confirmed the identification as these data matched the
previously published data exactly.16
The second metabolite (1) (Fraction D29, peak 6.1) gave an m/z of 1005.4698
[M+Na]+ following HRESIMS analysis suggesting a molecular formula of C51H66N8O12
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and 23 degrees of unsaturation (Figure S18). Dereplication efforts did not readily identify
a known micropeptin with this m/z value. The molecule was 14 Da less than micropeptin
996 and the 1H NMR and 13C NMR spectra of 1 and micropeptin 996 were nearly
identical and the presumption was a difference of a CH2 group between the two
compounds. Examination of 2D NMR data including HSQC, HMBC, COSY, TOCSY, and
NOESY spectra (Table 1 and Figures S1 and S13-S17) established spin systems and
connections for the following sequence of amino acids: valine, N-methyl phenylalanine,
phenylalanine, amino hydroxy piperidone (Ahp), tyrosine, threonine, glutamine, and
butyric acid. The difference being the substitution of a tyrosine in 1 for the homotyrosine
in micropeptin 996. The planar structure of 1 was also supported by MS/MS
fragmentation data, which identified a key fragment (m/z 404.1832) as Ahp-Phe-NMePhe-H2O (Figure S19).16 The relative configuration of the Ahp residue was assigned
based on NOE correlations between H-2Ahp, H-4aAhp, and H-5Ahp showing that these
hydrogens were co-planar. Additionally, the NH proton of the Ahp residue showed an
NOE correlation to H-3aAhp, which showed an NOE correlation to the OH group attached
to C-5Ahp (Figure S1). This was consistent with previously published research assigning
the relative configuration of the Ahp residue.16,17 Compound 1 was given the name
micropeptin 982, which is a general convention to designate these micropeptins by
molecular weight.
T2 1 Table 1. NMR data for micropeptin 982 (1) (500 MHz for 1H NMR, 125 MHz for 13C
NMR; DMSO-d6).
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The third metabolite (2) (Fraction D29, peak 6.2) gave an m/z of 980.4858
[M+Na]+ suggesting a molecular formula of C49H67N9O11 and 21 degrees of unsaturation
(Figure S24). Examination of the 1H NMR spectrum showed additional resonances in 2
in the region from 7.0 to 7.5 ppm and two shielded doublets (δH 0.88 and 0.75) that were
not present in 1 (Figure S20). Examination of the 1H NMR spectrum and 1H-1H 2D NMR
spectra (COSY, TOCSY, NOESY, Figures S21-S23) established spin systems
consistent with the following amino acids: valine, N-methyltryptophan, phenylalanine,
amino hydroxy piperidone (Ahp), valine, threonine, glutamine, and butyric acid. The
sequence of amino acids was established via NOE correlations, MS/MS data, and
analogy to previously characterized micropeptins. An NOE correlation between Ahp-OH
(δH 5.85) and H-9 of Phe (δH 6.78) supported that these residues were connected. The
MS/MS data showed a fragment m/z 443.1931, which supported the fragmentation of
Ahp-Phe-N-MeTrp-H2O (Figure S25). This left two positions in the peptide ring to be
occupied by valines along with ester formation by threonine and the Gln-BTA side chain.
The relative configuration of the Ahp residue was identical to that of 1 based on NOE
correlations and 2 was given the name micropeptin 957.
The absolute configuration of the amino acids in 1 and 2 was determined by acid
hydrolysis of both compounds. Next, we treated the hydrolysates with Marfey’s reagent
(L-FDAA) to generate derivatives, and finally we completed chromatographic
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comparison of the derivatized hydrolysates to authentic L- and D-amino acid standards
(Figures S26 and S27). All amino acids in both 1 and 2 matched L standards and the
configuration of the Ahp residues in both compounds is proposed based on relative
configuration and comparison to previously characterized micropeptins.
Biological Activity. Each micropeptin tested (1, 2, and micropeptin 996) showed the
ability to reduce NOS in BV-2 microglial cells following stimulation with bacterial LPS
(Figure 3). Approximately a 50% reduction in NOS was observed for doses of each
metabolite at 10 μM, and significant reduction in NOS was shown at concentrations as
low as 0.1 μM. We tested each metabolite for the ability to inhibit the protease plasmin
with the rationale that perhaps the anti-inflammatory activity was the result of the
inhibition of this protease in the cell. The activation of plasminogen to the protease
plasmin occurs in cellular inflammatory responses and plasminogen activation has
shown the ability to activate microglial cells.18,19 Additionally, other micropeptins have
shown the ability to inhibit plasmin.20 However, in vitro enzyme inhibition assays did not
show inhibition when concentrations of the micropeptins were tested up to 10 μM
concentrations (Figure S28).
In this report, we have isolated and characterized two new micropeptins (1 and
2), and we have evaluated the ability of three micropeptins (1, 2, micropeptin 996) to
reduce inflammation in BV-2 microglial cells. Micropeptins are a large class of
cyanobacterial peptides with over 82 variants,7 and a complicated nomenclature which
includes alternative names to micropeptin such as cyanopeptolin, aeruginopeptin,
anabaenopeptilide, oscillapeptilide, oscillapeptin among several others.7 However,
despite the many names, the chemistry is more consistent in this group as the class is
characterized by the 3-amino-6-hydroxy-2-piperidone (Ahp) residue and an ester linkage
formed by the β-hydroxy group of threonine and the carboxy group of the terminal amino
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acid. There are four other ring amino acids (six total), which can be variable and the
penultimate residue (from the point of view of biosynthesis) is N-methylated. There are
two additional residues not in the ring: one an amino acid and the other a fatty acid.
These characteristics are also observed in 1 and 2. Intriguingly, while these metabolites
are generally thought to be sequestered to cyanobacterial metabolism, a recent
cyanopeptolin isolated from a Streptomyces olivochromogenes strain provokes thoughts
as to the evolutionary history of this class of molecules.21 A consistent biological activity
observed in this class is protease inhibition in contrast to the phosphatase inhibition
observed from microcystins.22 For instance, micropeptin 996 was previously shown as a
potent inhibitor of chymotrypsin with an IC50 of 0.64 μM.16 Micropeptin T2 showed potent
inhibition of plasmin (IC50 = 0.1 μg/mL), while micropeptin T1 showed no ability to inhibit
this protease (IC50 > 100 μg/mL).20 The difference between the two metabolites was a
substitution of lysine in T2 instead of the tyrosine in T1 (in the same amino acid position
as tyrosine in 1). We observed no plasmin inhibition from 1, 2, or micropeptin 996 and
this may be due to specific amino acid residues conferring this activity to specific
micropeptins. Additional structure-activity relationship studies should prove illuminating
with respect to protease inhibition. Other micropeptins such as kyanamide, symplostatin
5, and tutuilamides A-C all showed potent inhibition of elastase.17,23,24
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F2 3

Figure 3. Anti-inflammatory activity of micropeptin 982 (MP 982) 1, micropeptin 957

(MP 957) 2, and micropeptin 996 (MP 996) tested against BV-2 murine microglial cells.
All data is expressed as mean ± standard error (n = 3), and the significance was
reported by analysis of variance (ANOVA) followed with Dunnett’s multiple comparison
procedure. Significance (α = 0.05) as compared with LPS, p ≤ 0.0002 (***) and p ≤
0.0001 (****).

Symplostatin 5 additionally alleviated inflammation in an epithelial lung airway model
system.22 We observed a reduction in inflammation in microglial cells after treatment with
the micropeptins reported in this study and further explorations of their mechanism of
action in microglial cells in warranted. For realistic therapeutic development of CNS drugs,
transport through the blood-brain barrier is essential. While microcystins have been shown
to rely on transportation through organic anionic transporters (OATs) to move into cells,25
less is known about the same transport of micropeptins. However, it will be essential to
determine the ability of micropeptins to cross the BBB to be realistic agents for reducing
neuroinflammation. In addition to the fraction (D29) that was further mined in this report,
there are several other fractions of interest that had the ability to reduce NOS levels in
LPS-stimulated microglial cells (Figure S3). Fraction D29 was chosen for further
purification because it showed the strongest reduction in NOS when tested at 10 μg/mL
and also showed no significant cytotoxic effects at the same concentration.

CONCLUSION
The metabolite profiling approach (LC-MS/MS molecular networking) was implemented in
our workflow and we quickly identified the micropeptin class in our active fraction. This
mass spectrometry-guided approach can be paired with bioassay data to identify likely
bioactive molecules in samples with many analytes.26 Molecular networking has been
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used to describe the chemical space in cyanobacterial harmful algal blooms,27,28 and
innovative approaches using this technology will continue to increase the efficiency of
therapeutic discovery efforts. There are many other likely micropeptins in this active
sample (Figure S4), and further isolations will allow for structure-activity relationship
studies to be carried out. There were clearly potent cytotoxins as well in the prefractionated
library, which may be of interest as potential chemotherapeutics or may be explored for
their environmental toxicity (Figure S2). High content and information-rich mass
spectrometry workflows paired with additional bioassays will be necessary to fully exploit
the potential of the wealth of metabolites in the prefractionated library.

MATERIALS AND METHODS
General Experimental Procedures. Optical rotations were acquired using a Jasco P2000 polarimeter. UV spectra were measured using a Beckman Coulter DU-800
spectrophotometer. NMR spectra were recorded using a Varian 500 MHz instrument. The
chemical shifts reported for 1, 2, and micropeptin 996 were referenced to the residual
solvent peaks of DMSO-d6 (δH 2.50 and δC 39.5). HRESIMS analysis was performed using
an AB SCIEX TripleTOF 4600 mass spectrometer with Analyst software. MS/MS data
were recorded on this same instrument using the product ion function. LC-MS/MS was
performed using a ThermoFisher LTQ XL mass spectrometer with an electrospray
ionization (ESI) source. Semi-preparative and analytical HPLC was carried out using a
Dionex UltiMate 3000 HPLC system equipped with a micro vacuum degasser, an
autosampler, and a diode-array detector.

Collection and Processing of Cyanobacterial Biomass into Prefraction Library.
Biomass was collected from a holding lagoon at the Muskegon County Wastewater
Management facility on Maple Island Road, Muskegon, Michigan, USA and concentration
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of biomass was completed as previously described.10 The biomass was lyophilized and
sent to AnalytiCon Discovery (Potsdam, Germany) for library fractionation. 10 kg of
lyophilized biomass powder was repeatedly extracted methanol, and separation over HP20 eluting in 10% MeOH steps resulted in a medium polarity fraction. Next preparative
HPLC generated the pre-fractionated library, which was partitioned into deep well plates
for initial biological testing.

LC-MS/MS-Based Molecular Networking. Fraction D29 was subjected to LC-MS/MS
analysis with a specific scan event recording MS/MS spectra in data-dependent
acquisition mode on a ThermoFisher LTQ XL mass spectrometer with an electrospray
ionization (ESI) source coupled to a Dionex UltiMate 3000 HPLC system equipped with a
micro vacuum degasser, an autosampler, and a diode-array detector. A Kinetex 5 μm C18
column (150 x 4.6 mm) was used for separation of analytes. The LC method consisted of
a linear gradient from 15% to 100% CH3CN in water + 0.1% formic acid over 20 min,
followed by an isocratic period at 100% CH3CN of 5 min. The flow rate was held constant
at 0.4 mL/min. The MS spray voltage was 3.5 kV with a capillary temperature of 325 °C.
For the MS/MS component, the CID isolation width was 1.0 and the collision energy was
35.0 eV. The raw data files were converted to mzXML format using MSConvert from the
ProteoWizard suite (http://proteowizard.sourceforge.net/tools.shtml). The molecular
network was generated using the online platform at Global Natural Products Social
Molecular Networking website (gnps.ucsd.edu) [27]. The data were processed by
removing all MS/MS fragment ions within +/- 17 Da of the precursor m/z. MS/MS spectra
were filtered by choosing only the top 6 fragment ions in the +/- 50 Da window throughout
the spectrum. The precursor ion mass tolerance was set to 2.0 Da with a MS/MS fragment
ion tolerance of 0.5 Da. A network was then created where edges were filtered to have a
cosine score above 0.6 and more than 2 matched peaks. The spectra in the network were
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then searched against GNPS' spectral libraries. The library spectra were filtered in the
same manner as the input data. All matches kept between network spectra and library
spectra were required to have a score above 0.6 and at least 2 matched peaks. The
network was visualized using the Browser Network Visualizer tool available on the gnps
website,29 and then imported into the program Cytoscape for additional analysis.

Isolation of 1 and 2. Fraction D29 from the prefractionated library was subjected to
reversed phase semi-preparative HPLC using a Kinetex 5 μm C18 column (250 x 10 mm)
and an isocratic method. Mobile phase: 65% CH3CN/35% H2O with 0.05% formic acid
added to each solvent and flow rate of 3 mL/min. Seven HPLC peaks (1-7) were collected
and subjected to the anti-inflammatory assay and an evaluation of purity using 1H NMR
and LC-MS. This first purification resulted in the isolation of 14 mg of micropeptin 996 (tR,
26.5 min, peak 7). Peak 6 (tR, 25 min) was further purified using a YMC 5 μm Chiral ART
Cellulose-SB column (250 x 4.6 mm) using an isocratic method. Mobile phase: 65%
CH3CN/35% H2O with 0.05% formic acid added to each solvent and flow rate of 1 mL/min.
Final purification resulted in the isolation of 12 mg of 1 (tR, 5.25 min, peak 6.1) and 2 mg
of 2 (tR, 10.75 min, peak 6.2).

Micropeptin 982 (1): colorless oil; [α]23D -65 (c 0.1, MeOH); UV (MeOH) λmax (log ε)
228

(4.8), 278 (4.1) nm; 1H NMR (500 MHz, DMSO-d6), and

DMSO-

13

C NMR (125 MHz,

d6), see Table 1; HRESIMS m/z 1005.4698 [M+Na]+ (calcd for

C51H66N8O12Na,

1005.4698).

Micropeptin 957 (2): colorless oil; [α]23D -23 (c 0.1, MeOH); UV (MeOH) λmax (log ε)
224

(4.8), 274 (3.9) nm; 1H NMR (500 MHz, DMSO-d6), see Table S1; HRESIMS m/z
980.4858 [M+Na]+ (calcd for C49H67N9O11Na, 980.4858).
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Marfey’s Analysis. To determine the absolute configuration of the α-amino acids in 1 and
2, 0.5 mg of each compound was reconstituted in 0.5 mL of 6 N HCl and heated at 110 °C
for 15 h. The hydrolysate was dried, reconstituted in 300 µL of 1 M NaHCO3 solution, and
treated with 50 µL of 1 mg/ml solution of N-α-(2,4-dinitro-5-fluorophenyl)-L-alanine amide
(L-FDAA) in acetone, followed by heating at 40 °C for 1 h. Next the mixture was cooled to
room temperature and quenched with 100 µL of 1 N HCl. The hydrolysate was dried and
reconstituted in 200 µL of CH3CN and filtered through a 0.2 µm filter. The hydrolysate and
the L-FDAA derivatized α-amino acid standards were subjected to HPLC analysis (20%
H2O/CH3CN + 0.1% FA to 50% H2O/ CH3CN + 0.1% FA over 30 min and then back to
initial conditions from 31-36 min; Kinetex C18 column, 150 × 4.6 mm, flow rate 0.6
mL/min). The retention time (min) of the hydrolysate of 1 matched L-Val (20.4; D-Val, 23.1),
L-N-MePhe
L-Thr

(23.6; D-N-MePhe, 23.9), L-Phe (23.3; D-Phe, 25.1), L-Tyr (18.4, D-Tyr, 19.6),

(12.5; D-Thr, 15.3; L-allo-Thr, 12.7; D-allo-Thr, 13.8), and L-Gln (11.6; D-Gln, 12.0).

The retention times (min) of the hydrolysate of 2 matched L-Val (20.4; D-Val, 23.1), L-NMeTrp (21.6; D-N-MeTrp, 22.4), L-Phe (23.3; D-Phe, 25.1), L-Thr (12.5; D-Tyr, 15.3; L-alloThr, 12.7; D-allo-Thr, 13.8), and L-Gln (11.6; D-Gln, 12.0).

Biological Assays. BV-2 murine microglial cells were cultured as previously described.6
The cytotoxicity of the library fractions and pure compounds to the cells was measured
using the CellTiter-Glo® Luminescent Cell Viability Assay (CTG, Promega, Fitchburg, WI).
BV-2 cells were treated with trypsin and seeded in a white-walled 96-well plate (Corning,
Corning, NY) at 100,000 cells/mL in DMEM/F-12 media. Cells were allowed to adhere for
24 h in the incubator followed by treatment with the fractions at 10 μg/mL concentrations
and eventually pure compounds at final concentrations of 10 µM, 1 µM, and 0.1 µM. After
dosing, the cells were incubated with fractions or pure compounds for 24 h. Following
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incubation, the cell viability was measured following manufacturer’s protocols. The CTG
buffer and substrate were combined, and 100 μL of mixed reagent was added to each well
followed by two minutes of slow shaking on an orbital shaker, then 10 minutes of nonshaking equilibration time. The luminescence was measured using a SpectraMax M2
Plate Reader. Cell viability was then reported as a percent of vehicle control (DMSO). In
order to test for anti-inflammatory activity, the Griess assay was used. The Griess assay
reagent kit was purchased from Promega Corp (Fitchburg, WI, USA). BV-2 cells were
plated in a 24-well plate at 100,000 cells/mL in complete media. Cells were treated with
fractions or pure compounds for 1 h at the same concentrations used for the cell viability
assays. After incubation, BV-2 microglia were exposed to (LPS) at 1 µg/mL for 23 h. After
incubation, 50 µL aliquots were taken from each well and transferred to a clear 96-well
plate where Griess reagents were added for total nitric oxide concentration determination
compared to the control wells of DMSO. Statistical significance was determined using a
One-way ANOVA followed by a Dunnett’s post hoc test, and analysis was performed using
the program Prism (San Diego, CA).
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ABSTRACT:
To combat the bottlenecks in drug discovery and development, a pipeline to identify
neuropharmacological candidates using in silico, in vitro, and receptor specific assays
was devised. The focus of this pipeline was to identify metabolites with the ability to
reduce neuroinflammation, due to the implications that chronic neuroinflammation has in
chronic pain and neurodegenerative diseases. A library of pure compounds isolated from
the cyanobacterium Trichodesmium thiebautii was evaluated using this method. In silico
analysis of drug likelihood and in vitro permeability analysis using the parallel artificial
membrane permeability assay (PAMPA) highlighted multiple metabolites of interest from
the library. Murine BV-2 microglia were used in conjunction with the Griess assay to
determine if metabolites could reduce lipopolysaccharide-induced neuroinflammation
followed by analysis of pro-inflammatory cytokine concentrations in the supernatant of
the treated cell cultures. The nontoxic metabolite unnarmicin D was further evaluated
due to its moderate permeability in the PAMPA assay, promising ADME data,
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modulation of all cytokines tested, and prediction as an opioid receptor ligand. Molecular
modeling of unnarmicin D to the mu and delta opioid receptors showed strong theoretical
binding potential to the mu opioid receptor. In vitro binding assays validated this pipeline
showing low micromolar binding affinity for the mu opioid receptor launching the
potential for further analysis of unnarmicin D derivatives for the treatment of pain and
neuroinflammation related diseases.
Keywords: neuroinflammation, mu opioid receptor, delta opioid receptor, modeling
INTRODUCTION
The human brain has evolved in the presence of natural sources of CNSstimulating molecules for millennia. From the discovery of neuroactive alkaloids in the
Papaver somniferum plant in 3500 BCE, to more recent discoveries of the first marine
derived delta opioid agonists there is bountiful evidence that organisms produce
metabolites that are capable of binding to the receptors in the human brain.1,2 Recently,
cyanobacterial secondary metabolites have been showcased for their
neuropharmacological potential.3 Our laboratory has isolated a panel of new-to-science
metabolites from a Trichodesmium thiebautii bloom, some with moderate cytotoxicity to
human neuronal cells, but otherwise undetermined bioactivity.4–6 Harnessing the unique
chemistry of nature for the development of pharmaceutical drugs that target brain
diseases is an ongoing interest to natural product chemists, but a challenging endeavor
in drug discovery.
It is critical to continue developing neuropharmacological drugs due to the
increasing prevalence of neurodegenerative diseases in recent decades and the
prediction that numbers will continue to rise in the future, with little known treatment
options for these diseases. The risk of developing a neurodegenerative disease
increases with age; an assessment of people with Alzheimer’s disease (AD) in 2016

68

determined that out of the 5.4 million patients who had AD, 5.2 million were over the age
of 65.7 Due to recent medical advances, humans are living longer than ever and
neurodegenerative diseases are undoubtedly going to have significant health and
economic impacts on the US healthcare system.8
Chronic, uncontrolled neuroinflammation is a main driver in the development
neurodegenerative diseases such as AD and Parkinson’s Disease.9,10 Prolonged
exposure to opioid drugs can also induce inflammation in the brain and increase the
production of pro-inflammatory cytokines within the neuroaxis.11 These pro-inflammatory
elements such as IL-1β, TNFα, and IL-6 are found in elevated levels in patients who
suffer from chronic pain. The treatment of chronic pain with opioids can be detrimental to
the integrity and stability of neuronal and mental health and heighten the risk of
developing a neurodegenerative disease in the future.12 In the face of the current opioid
epidemic, it is uncertain what the long-term side effects will arise for the cohort of people
affected by the addictive nature of these drugs. Focusing drug development pipelines at
reducing inflammation in the brain will result in both acute and long-term benefits for
patients.
Current opioid analgesics have rapid permeation through the blood brain barrier
(BBB) as well as nanomolar binding affinity to the mu opioid receptor, they are often
abused and consumed in ways that proliferate their addictive qualities.13 The detrimental
side effects of these drugs provide rationale for the development of drugs that target
other receptors involved in nociception such as the delta opioid receptor, or partial
agonist/antagonist drugs that interact with multiple receptors for the treatment of pain.
The idea of slowing pharmacokinetics can be a beneficial approach in separating the
positive response associated with taking a drug, which can lead to downstream
decreases in addiction rates.14
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Agonism of the mu opioid receptor often results in activation of the central
dopamine reward pathways resulting in a euphoric response and increase in addiction
potential.15 Apart from the mu opioid receptor (µ, MOR) there are three other known
opioid receptors in the human brain: the delta opioid receptor (δ, DOR), the kappa opioid
receptor (κ, KOR), and the nociceptin receptor (NOR). The majority of current and past
analgesic drugs such as morphine and oxycodone target the mu opioid receptor and
subsequently the MOR is also the most heavily researched opioid receptor.16,17 Recent
research has focused on other opioid receptors such as the DOR as a new drug target,
due to its ability to induce nociceptive pathways and the lessened potential for addiction
compared to the MOR.18 Further, the polypharmacological activity of compounds
interacting with multiple opioid receptors is of emerging interest for the treatment of pain.
A notable example is the bifunctional peptide biphalin, which shows high affinity binding
to both the MOR and the DOR and produces potent analgesic activity with less
dependence compared to other opioids.19,20 This bifunctional interaction has been
investigated, using mainly synthetic molecules, in other MOR/DOR combinations,
MOR/NOR combinations, and MOR/KOR combinations.21-23 Additionally, mitragynine
analogs have shown promise as analgesics with a mechanism of action of MOR
agonism and DOR antagonism.24 These analogs did not recruit β-arrestin-2 following
receptor binding, which limits tolerance and dependence.24
There is an immense need for new analgesic drugs, and drugs that reduce
neuroinflammation. Due to the plethora of obstacles associated with developing a
candidate drug for neurodegenerative diseases, discovery and development rates are
low. Approval rates for central nervous system (CNS) drugs are about half compared to
non-CNS drugs and marketing approval takes over 30% longer for CNS drugs.25 Oral
administration of drugs leads to greater compliance in patients compared to other
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methods of administration.26,27 However, formulation of oral drugs that can subsequently
cross the BBB after entering the blood stream is difficult to test in early stage
development of pharmaceuticals. Additionally, many drugs are subsequently
metabolized by enzymes after ingestion or are flushed out of the brain via efflux
transporters. To save time and money there needs to be a method for identifying
potential CNS drug candidates early in the discovery process that are permeable, safe,
and efficacious.
Herein, we propose a pipeline using in silico and in vitro methods for screening a
pure compound library comprised of cyanobacterial secondary metabolites from
Trichodesmium thiebautii.28 Compounds were first screened for their drug-likelihood using
the online platforms SWISS ADME, and SWISS target predictor.29,30 Each compound was
then tested for in vitro permeability analysis through an artificial BBB using the parallel
artificial membrane permeability assay (PAMPA).31 Permeable compounds were further
investigated for cytotoxicity in murine BV-2 cells, and their ability to reduce LPS induced
neuroinflammation through the Griess assay. The inflammatory response of the LPSinduced microglia was further analyzed by investigating various pro-inflammatory
cytokines via enzyme-linked immunosorbent assay (ELISA). Compounds predicted to
cross the BBB, exhibited promising ADME, and reduced inflammatory biomarkers were
further evaluated using molecular modeling to the SWISS predicted candidate protein
targets.
Lastly, metabolite(s) that showed promise throughout these screening
techniques were evaluated for binding affinity in receptor specific assays. Using this
approach, we have identified the metabolite unnarmicin D as an opioid receptor ligand
with affinity for both the mu opioid receptor (MOR) and the delta opioid receptor.
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Unnarmicin D also produced significant anti-inflammatory activity in cell-based assays
furthering the therapeutic potential in inflammatory diseases.
RESULTS AND DISCUSSION
In Silico Analysis of the Cyanobacterial Pure Compound Library. The pure
compound library of cyanobacterial metabolites (Figure 1, Table S1) was first subjected
to in silico evaluation based on the physiochemical attributes the metabolites possessed
as an early indication of drug-likelihood. This process included thorough screening of
metabolites through the platforms SWISS-ADME and SWISS Target Predictor (Table
S2, Table S3). Various physiochemical parameters were evaluated such as lipophilicity,
water solubility, and pharmacokinetics. Inhibition of cytochrome enzymes often causes
adverse effects in vivo and the predicted inhibition of CYP enzymes was a negative
attribute of the metabolite. Similar investigations have been completed for in silico drug
likeness for neuropharmacological drugs.32,33 Lipinski, Ghose, Verber, Egan, and
Muegge have all published parameters or “rules” for drug likelihood, and although this
was used as a generalization due to the leniency of these rules in regards to natural
products, violations of these rules were thought to be disadvantageous. The synthetic
accessibility was measured in the software program on a scale from 1 (easy) to 10
(difficult). The value is based on the availability of chemical structures from commercial
vendors with the assumption that more frequently encountered structures are more
synthetically accessible. Additional components to the synthetic accessibility score are
size and complexity. If a natural product derived metabolite were to continue down the
drug development pipeline, it would eventually need to be synthesized to gather enough
material for animal and human studies. Some parameters that were of particular interest
were logP and polar surface area (PSA) due to the relationship between permeability
and these physiochemical parameters. Three metabolites were highlighted during this
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screening process: GH2I1 (tricholactone), EF1E (trichophycin B), and GH2C1
(unnarmicin D). Unnarmicin D, which is a peptide molecule, has more than five nitrogen
and oxygen atoms, which deems this molecule improbable for crossing the BBB
according to Österberg and colleagues.34 The number of N and O atoms in a molecule is
used as a proxy for PSA because they are the main hydrogen bond acceptors. However,
for unnarmicin D and tricholactone (GH2I1), the logP values calculated by these
platforms fall very close to the optimal logP for CNS penetrable drugs. This logP range
developed by Hansch and Leo determined the optimal range to be 1.5 to 2.7; the
calculated logP values for unnarmicin D and tricholactone were 2.76 and 2.63
respectively. 35-37 Continuing down the pipeline, the metabolites were analyzed using the
SWISS target predictor. Human drug targets were improbable for two of the three
metabolites, but unnarmacin D (GH2C1) showed the highest probability of being a Gprotein coupled receptor ligand (Figure S1) with moderate probability of being both a mu
and delta opioid ligand (Table S3).
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F3 1 Figure 1: Sixteen secondary metabolites isolated in our laboratory from a
Trichodesmium thiebautii collection that were chosen for further analysis detailed in this
report. Molecules are designated by their name and laboratory code, e.g. unnarmicin D
= GH2C1.

Evaluation of In Vitro Permeability of Pure Compounds through the BBB via
PAMPA. The first in vitro assay employed in this pipeline was the parallel artificial
membrane permeability assay (PAMPA) to assess the passive transport of metabolites
through a membrane designed to simulate the BBB. This is often a roadblock in drug
discovery, although it was hypothesized that most metabolites in this library would pass
the membrane because they are small lipophilic molecules. Using this method, all
metabolites showed good to moderate permeability except for the alkyne containing
metabolite trichotoxin B (D2F1) (Figure 2A). It should be noted that this assay is only
assessing passive permeability, and in biological systems there are many factors at play
such as active transporters to bring metabolites into the brain and transporters that efflux
unwanted xenobiotics from the brain.38 The PAMPA software calculates the -LogPe by
detecting the unique chromophore of each metabolite in the donor and acceptor wells
and comparing the intensity to that of the reference plate. To confirm the results from the
UV PAMPA plate, the chromatography fraction (fraction “G”) from the original
cyanobacterial extraction (Figure S2) was subjected to PAMPA analysis to determine if
the compounds that were permeable in their pure form could be detected in a lessrarefied solution. Using the fragmentation pattern identified on a HIRES-TOF-MS for
three metabolites isolated from this fraction (GH2C1, GH2D8, and GH2N1), transitions
were monitored for each metabolite on a Sciex Qtrap 4500 mass spectrometer (Table
S4). The permeability was assessed using the area under the curve (AUC) for each
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peak in the resulting chromatogram. All three samples showed permeability using this
analysis (Figure 2B). Verapamil was used as the positive control, and theophylline as the
negative control. For each compound, a reference measurement was taken before the
PAMPA was run, this value was normalized to 100% and the acceptor plate was
analyzed via MS to give a percent recovery value using the area under the curve for the
detected metabolite. The results from the chromatography fraction are consistent with
the data shown in the UV plate with the pure compounds, providing additional support
for this method of permeability analysis.

F3 2 Figure 2: A. The permeability of pure compounds isolated from Trichodesmium
thiebautii were evaluated for their in vitro passive permeability through the BBB.
Theophylline was used as a poorly permeable control, corticosterone as a moderately
permeable control, and verapamil HCl as a highly permeable control. B. Fraction G from
the original fractionation of the cyanobacterial extract was evaluated in the PAMPA
assay. The AUC of each metabolite in the reference well was normalized to 100%, the
AUC for the acceptor well (right bar) is shown as a percent of reference material (left
bar), n=6.
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It was originally hypothesized that peptide molecules were unable to pass the
BBB. However, many studies have proven this incorrect with both exogenous and
endogenous peptides.39-42 However, peptides do contain a high number of amide bonds
and hydrogen bond acceptors, which are unfavorable for passively crossing the BBB.43
This combined with the relatively high molecular weight of unnarmicin D for a CNS drug
(622 Da) could result in reduced transport across the BBB. The lipophilic tail that
unnarmicin D possesses increases the overall lipophilicity of the molecule and likely
contributes to its ability to attach to membranes or passively cross them. Furthermore,
N-methylation, increased ring size, or changes configuration may help increase the
passive permeability of this metabolite for future studies.44 Peptide transport is not a
static process across the BBB and can change based on the needs of the CNS and the
physiochemical environment, which in the case of chronic pain, inflammation, or opioid
use could be extremely variable between patients.45

Murine BV-2 Cell Analysis of Cytotoxicity and Reduction in Inflammatory
Biomarkers. Following permeability analysis, compounds were subjected to cell-based
analysis of toxicity and inflammatory modulation. Murine microglia cells were chosen as
a model for neuroinflammation due to the presence of opioid receptors and previous
nociception related studies with this cell line.6 The BV-2 cell viability in the presence of
the cyanobacterial metabolites was first assessed at concentrations 10 µM, 5 µM, and 1
µM (Figure S3). Trichophycin B (EF1E) was previously identified as a potential drug
candidate from ADME screens (Table S2, Table S3), but was too toxic to continue
testing in downstream assays. All other metabolites were further evaluated for their
potential to reduce LPS induced neuroinflammation via the Griess assay at 5 µM
concentrations.
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F3 3 Figure 3: Murine microglia (BV-2) cells were pre-treated with cyanobacterial

metabolites at 5 µM for one hour followed by an LPS-induced inflammation period of 23
h. Cell culture supernatant was harvested from the treated wells and was used for the
analysis of A. NOS, B. TNFα, C. IL-6, and D. sTLR-2. All data is expressed as mean ±
standard error (n = 3), the significance was reported by analysis of variance (ANOVA)
followed with Dunnett’s multiple comparison procedure. Significance as compared with
control DMSO p ≤ 0.03 (#), p ≤ 0.002 (##), p ≤ 0.0002 (###) and p ≤ 0.0001 (####); as
compared with LPS, p ≤ 0.03 (*), p ≤ 0.002 (**), p ≤ 0.0002 (***) and p ≤ 0.0001 (****).
Nitric oxide species (NOS) are gaseous signaling molecules that has been
shown to influence various neurological factors such as neurotransmitter release,
synaptic plasticity, neuronal death, and autophagy.47,48 Neuronal damage induced by
excessive NOS has been hypothesized as a key factor in neurodegenerative diseases
such as Alzheimer’s Disease, Parkinson’s Disease, and strokes.10,49,50 NOS is highly
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expressed following activation from various stimuli, including LPS.51 We evaluated the
potential of the cyanobacterial metabolites to reduce NOS levels following LPS
activation. Thirteen metabolites were tested at 5 µM and seven were able to significantly
reduce the NOS levels in the cell culture media (Figure 4A). The metabolite GH2I1,
which was highlighted as a potential therapeutic metabolite during the ADME screens,
did not significantly reduce NOS levels. The seven metabolites that significantly lowered
NOS were further evaluated for their ability to reduce pro-inflammatory cytokines TNF-α
and IL-6. Multiple metabolites tested significantly reduced the levels of IL-6 (Figure 3B)
produced by the murine microglia cells, however, only unnarmicin D significantly lowered
levels of TNF-α (Figure 3C). Following LPS induced inflammation, unnarmicin D was
able to significantly increase the levels of soluble TLR2 (sTLR2) (Figure 3D).
Toll-like receptors (TLRs) are innate immune receptors in the human body that
recognize endogenous and exogenous molecular patterns resulting in inflammatory
signaling.52 In the central nervous system, microglia, astrocytes, neurons, and
oligodendrocytes are all known to express certain TLRs.53 These receptors are involved
in a variety of signaling pathways which mediate NOS secretion, and induce the
expression of inflammatory genes for immune regulation.54 Soluble TLR-2 (sTLR2), has
been found to suppress TLR-2 mediated inflammation by preventing the binding to other
co-receptors, resulting in reduced inflammatory response.55,56 After LPS induced
inflammation, unnarmicin D was able to significantly increase the levels of soluble TLR2
indicating a downstream decrease in the TLR2 mediated inflammatory response. The
combination of a decrease in various pro-inflammatory cytokines and an increase in
sTLR-2 indicates that unnarmicin D has anti-inflammatory potential, as investigated in
murine microglia.

78

After cytokine analysis, unnarmicin D was highlighted as the lead molecule in this
study. Therefore, an analog of the molecule was synthesized to produce enough product
for further downstream analysis (Figures S4-S8). The lipophilic tail of the synthetic
molecule is two carbons shorter than the organic molecule due to synthetic precursor
availability. To ensure the activity of the analog was consistent with the natural product,
the Griess assay was repeated and showed similar anti-inflammatory activity of both
molecules (Figure S9). The unnarmicin D analog was used for all further receptor
binding and activity assays. Further, comparing the structure of unnarmicin D with other
neuroactive peptides such as the endogenous opioid ligand leu-enkephalin (Figure S10)
provided rationale for hydrolyzing the ester bond to create a linear peptide. However,
upon base hydrolysis of the ester to obtain the linear molecule (Figures S10-S13), the
inflammatory response was diminished in comparison to the cyclic product (Figure S9).
The molecular modeling showed less favorable binding to both the MOR and the DOR,
significant ligand exposure remained, and predicted binding to the MOR in an allosteric
site in comparison to the cyclic product, which was predicted to bind in the orthosteric
binding site (Figure S14). This change may be due to increased flexibility of the linear
molecule in the binding pocket.
Molecular Modeling and in silico Analysis of Unnarmicin D and Derivatives
Structural analysis of the unnarmicin D analog shows some consistency with
other known opioid ligands such as morphine, leu-enkephalin, and mitragynine.
Unnarmicin D already contains a phenolic hydroxyl group (tyrosine) and a benzene
residue (phenylalanine), consistent with these other active metabolites, but lacks the
presence of a tertiary amine.57
Molecular modeling was performed with the analog using the molecular operating
environment (MOE) on both the mu opioid receptor (6DDF) and the delta opioid
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receptors (6PT2) using crystallized structures available in the protein data bank (PDB).
These receptors were chosen because they were both crystalized with a small peptidic
agonist. However, upon modeling with the DOR agonist bound receptor 6PT2, a
significant portion of the ligand was exposed, resulting in poor theoretical binding. This
may be due to the conformational change, which occurs after agonist binding, and in
comparison to the MOR modeling, this receptor does not contain the Gi complex. For
this reason, modeling calculations were completed for the agonist bound conformation
(Figure S15A, PDB 6PT2), the antagonist bound conformation (Figure S15B, PDB
4EJ4), and the non-ligand bound conformation (Figure S15C, 4N6H).
Molecular modeling of the unnarmicin D analog in the MOR revealed multiple key
interactions between the ligand and the receptor, which are critical for opioid activity.
Shim et al. noted that the most important interaction to predict mu opioid binding is the
interaction between the Asp147 residue in the binding pocket with a nitrogen on the
ligand; this interaction plays a direct role in receptor activation and has been validated
through mutagenesis studies (Figure 4A, Figure 4B).58 Examining the theoretical binding
in the 3D diagram of the analog (Figure 4A, inset) in the MOR binding pocket, this acidic
Asp147 residue interacts with three nitrogen atoms, stabilizing the confirmation of the
ligand in the receptor. Further, the π-π stacking interaction between the aromatic Trp293
residue and the tyrosine residue of the unnarmicin D analog increases the likelihood of
binding (Figure 4B), although this interaction can result in either antagonist or agonistic
functionality.58 Three of the carbonyls of the peptide’s amide bonds interact with the
Gln124, His297, and Tyr148 residues in the binding pocket, acting as hydrogen bond
acceptors, which further adds to the stability of this molecule in this conformation. The
lipophilic tail and the phenylalanine residue of the analog are exposed in the binding site
of the MOR as denoted by the blue color around the atoms. This area of ligand exposure
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with no receptor interactions would likely be the first place to begin an SAR study with
additional unnarmicin D derivatives. The ligand exposure led to the modeling of an
unnarmicin D derivative without a lipophilic tail to determine if theoretical binding would
be increased with less ligand exposure (Figure S16A). A methyl group replaced the
seven carbon lipophilic tail and the ligands interacted with the receptor in the same
location as the natural product, however, the aspartic acid residue (Asp147) in the
binding pocket, which is critical for receptor activation, was now only coordinating with
one amide nitrogen on the ligand compared to the tri-interaction observed with the
unnarmicin D analog (cf. Figure 4, Figure S16, and Table S5). Removal of this lipophilic
portion of the ligand would likely decrease the passive permeability through important
biological membranes such as the BBB due to decreased lipophilicity.
When examining the unnarmicin D analog interaction with DOR, molecular
modeling to the agonist and antagonist bound DOR receptors resulted in significant
ligand exposure in the receptor and poor binding constants (Figure S15A-B, Table S5).
Modeling to the antagonist molecule (Figure S15B) showed no interactions with the
receptor binding pocket. However, the unbound receptor (PDB 4N6H), displayed
promising modeling data (Figure S15C). Like the MOR, the DOR modeling with the
unbound receptor shows a key theoretical receptor-ligand interaction with the Asp95
residue with an amide nitrogen on the ligand. This interaction is associated with the
agonist binding domain of the DOR and is necessary for selective agonist binding in this
receptor.59 Further, this highly conserved polar Asp95 residue has been highlighted by
multiple studies as one of the positions, which holds the sodium ion in place to facilitate
protein conformation stability and peptide binding resulting in downstream agonistic
activity. 58-60 This interaction was observed in our modeling study when water molecules
were included in the binding predictions for the unbound receptor 4N6H (Figure S17 C
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and D). Similarly, using the agonist bound receptor (PDB 6TP2) the guanidinium group
of the Arg 257 residue in the binding pocket of the DOR (Figure S17A) participates in
hydrogen binding with the carbonyl of a glycine amino acid in the unnarmicin D analog,
allowing a hydrogen bonding network that extends through intermolecular interactions
then to the Arg 241 guanidinium group on the other side of the receptor where weak and
strong hydrogen bonding is predicted.

F3 4 Figure 4: Moleular modeling of unnarmicin D in the MOR (6DDF) A.) 3D diagram of
the ligand in the MOR receptor pocket. B.) A 2D diagram of the ligand-receptor
interactions.

Water molecules play an important role in the ligand stabilization and receptor
activation in many GPCRs.61,62 There are functional restrictions in predicting the role that
water molecules play during GPCR activation due to water molecule flexibility and
mobility as well as receptors constantly changing conformation.63 However, modeling
was performed in the presence of water molecules to determine if theoretical binding
would significantly change. For both the DOR and the MOR, binding calculations in the
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presence of water molecules did not significantly enhance binding in probability or the
strength of the ligand-receptor interaction (Figure S17).
Receptor-Target Analysis of Unnarmicin D at the Delta and Mu Opioid Receptors.
Radioligand binding assays of unnarmicin D to the delta opioid and mu opioid receptors
confirms that this ligand has affinity for both opioid receptors. The percent inhibition of
the control was used to measure the specific binding. For the delta opioid receptor, the
DOR specific ligand DPDPE was used as the control and for the mu opioid receptor
DAMGO was used as the control. Unnarmicin D showed stronger binding affinity to the
mu opioid receptor compared to the delta opioid receptor with a Ki value of 6.4 µM for
the MOR (Figure 5A) and a Ki value 21 µM for DOR (Figure 5B, Figures S18-S20).
Although these data show higher Ki values compared to analgesic drugs currently
available, these data show promising results for further medicinal chemistry advances on
this compound. The weak binding potential of the linear molecule predicted by modeling
was confirmed in the binding assay as this ligand showed no binding ability (Figure S21).

F3 5 Figure 5: Unnarmicin D radioligand binding as percent inhibition of control
compound. (A.) Unnarmicin D as percent inhibition of the agonist DAMGO at the mu
opioid receptor. Displaying an in vitro IC50 of 16 μM and a Ki 6.4 μM. (B.) Unnarmicin D
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as percent inhibition of the agonist DPDPE at the delta opioid receptor. Displaying an in
vitro IC50 of 38 μM and Ki 21 μM.

CONCLUSION
In this report, we demonstrated that the cyanobacterial metabolite unnarmicin D
is an opioid receptor ligand with affinity for both the mu and delta opioid receptors.
Furthermore, we have demonstrated that this molecule is non-toxic to murine microglia
cells and can reduce inflammation in cell-based systems through modification of cell
signaling molecules nitric oxide, TNFα, IL-6, and sTLR-2. A paradigm shift towards
focusing drug development to moderate chronic pain that focuses on a reduction in
neuroinflammation combined with opioid receptor activity could facilitate potential drug
candidates that can disrupt the cycle of inflammation followed by mood disorders and
addiction. Further, outside the realm of neuropharmacological drugs, an antiinflammatory opioid drug may have implications in inflammatory diseases such as
Crohn’s Disease and ulcerative colitis, where mu opioid agonists such as the synthetic
ligand DALDA have shown to be effective in reducing disease flares,64 and the dual
MOR/DOR agonist biphalin has also showed promise as a new therapeutic.65 These
data show promising results for further therapeutic development of unnarmicin D. The
development of an SAR study modifying unnarmicin D with varying amino acids and
lipophilic substituents to maintain activity but hone in specificity is needed as well as
testing a panel of receptors to assess the selectivity of unnarmicin D to the remaining
opioid receptors and other GPCRs, especially KOR and NOR. The utilization of this
pipeline prioritized compounds with BBB permeability, in vitro therapeutic activity, and
important potential molecular targets. While we focused on screening metabolites from a
cyanobacterial collection, the methods proposed here can be utilized for any metabolite
library, chromatography fractions, or extract library.
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EXPERIMENTAL SECTION
General Experimental Procedures. NMR spectra were collected using either a Bruker
800 MHz, Varian 500 MHz, or Bruker 300 MHz instrument. The chemical shifts reported
were referenced to the residual solvent peaks of either CDCl3, DMSO-d6, and MeOH-d4.
HRMS analysis was performed using an SCIEX TripleTOF 4600 mass spectrometer with
Analyst TF software. MS/MS was acquired using a SCIEX Qtrap 4500 coupled to a
Shimadzu Prominence UFLC system consisting of three LC-20AD pumps, a DGU-20A
degassing unit, SIL-20AC auto sampler, CTO-20AC column oven and CBM-20A
communication bus module. Semi-preparative and analytical HPLC was carried out
using a Dionex UltiMate 3000 HPLC system equipped with a micro vacuum degasser,
an autosampler, and a diode-array detector.

Biological Material, Collection, and Identification. The pure compound library was
comprised of cyanobacterial metabolites previously discovered in our laboratory. The
metabolites were isolated from Trichodesmium thiebautii extracts and verified for purity
using 1H NMR and HPLC-UV. All metabolites tested showed greater or equal to 95%
purity except for synthetic unnarmicin D (94%), conulothiazole C (90%) and trichotoxin B
(87%) (Figures S22-S37).

In Silico Modeling Using SWISS Target Predictor and SWISS ADME. SMILES files
for each compound were entered into the online platforms SWISS ADME
(http://www.swissadme.ch/) and SWISS target predictor
(http://www.swisstargetprediction.ch/) for the prediction of critical physiological
parameters attributed to drug candidates and drug targets. The full list of compounds
entered into the spreadsheet with conditional formatting can be found in the
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supplemental data (Table S1). Lipophilicity was measured using LogP and LogS, as well
as the program’s algorithms for determining if the candidate molecule would pass the
BBB and absorb into the human gut. Swiss target predictor was utilized with the
specifications of Homo sapiens being the target organism for this study. For each
metabolite screened, the main neuronal receptor target was recorded (Table S2).
Evaluation of In Vitro Permeability of Pure Compounds through the BBB via
PAMPA. The quantification of permeability and calculation of -LogPe is performed by
comparing the UV absorbance of the donor plate where the compound is initially added
to the UV absorbance of the acceptor well on the other side of the BBB simulation
membrane and comparing these data to that of the reference plate and blank plate. All
reagents for PAMPA were purchased from Pion Inc. (Billerica, MA, USA). Prisma HT
buffer was brought to pH 7.2 using 0.5 M sodium hydroxide. Five µL of 10 mM of each
pure test compound was diluted in 1 mL of pH adjusted buffer then mixed in the deep
well plate. Pion BBB lipid matrix was added to the bottom of each filter membrane then
the diluted compound was added to the donor well of the plate. The acceptor well
contained BBB acceptor solution. Once the sandwich assay was assembled, the plate
incubated for four hours in the PION GIT box. Following incubation, all plates were read
for UV absorbance from 190 nm-800 nm using a SpectraMax M2 multi-mode plate
reader (Molecular Devices, San Jose,CA).
Evaluation of In Vitro Permeability of Compounds in a Rarefied Extract through
the BBB via PAMPA. Chromatography fraction G from the original rarefication of the
crude cyanobacterial extract was evaluated using PAMPA. The same method was used
as described above. Following the PAMPA protocol, the plates were evaluated using LCMS/MS with MRM on a SCIEX Qtrap 4500 mass spectrometer. The transitions for each
monitored metabolite were determined utilizing the product ion function of a SCIEX
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HIRES TripleTOF 4600 mass spectrometer with Analyst TF software. The relative
quantity of metabolites was measured using the area under the curve (AUC) for each
metabolite. The closer the AUC of the donor and the acceptor plate shows higher
permeability.
Murine BV-2 Microglia General Cell Culture. Murine BV-2 microglia were a kind gift
from Grace Y. Sun (University of Missouri at Columbia, MO, USA). Cells were
maintained in 10% heat inactivated FBS, with 1% Penicillin/streptomycin (100 U/mL
penicillin, 100 mg/mL streptomycin) in high glucose (4.5 g/L) DMEM/F-12 media at 37°C
with 5% CO2. The cyanobacteria secondary metabolites were reconstituted in sterile
DMSO to obtain 10 mM stock solutions, then diluted in serum free media to relevant
concentrations. The control wells were treated with DMSO in serum free media.
Effects of Cyanobacteria Metabolites on BV-2 Microglia Cell Viability. The
cytotoxicity of the compounds to murine microglial (BV-2) cells was measured using
CellTiter-Glo® Luminescent Cell Viability Assay (CTG, Promega, Fitchburg, WI). BV-2
cells were treated with trypsin and seeded in a white-walled 96-well plate (Corning,
Corning, NY) at 100,000 cells/mL in DMEM/F-12 media. Cells were allowed to adhere
for 24 h in the incubator followed by treatment with the cyanobacteria metabolites at 10
µM, 5 µM, and 1 µM. After dosing, the cells were incubated with the metabolites for 24 h.
Following incubation, the cell viability was measured following manufacturers protocols.
The CTG buffer and substrate were combined, and 100 μL of mixed reagent was added
to each well followed by two minutes of slow shaking on an orbital shaker, then 10
minutes of non-shaking equilibration time. The luminescence was measured using a
SpectraMax M2 Plate Reader. Cell viability was then reported as a percent of vehicle
control (DMSO).
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Measurement of Nitric Oxide Species (NOS) in Murine BV-2 Cells via Griess Assay.
The Griess assay reagent kit was purchased from Promega Corp (Fitchburg, WI, USA).
BV-2 cells were plated in a 24-well plate at 100,000 cells/mL in complete media. Cells
were treated with cyanobacteria metabolites at 5 µM for 1 h. After incubation, BV-2
microglia were exposed to (LPS) at 1 µg/mL for 23 h. After incubation, 50 µL aliquots
were taken from each well and transferred to a clear 96-well plate where Griess
reagents were added for total nitric oxide concentration determination compared to the
control wells of DMSO.
Enzyme-Linked Immunosorbent Assay (ELISA) Analysis of TNFa, IL-6, and sTLR-2
in Cell Supernatant. Following the Griess assay, the supernatant from cell culture
experiments was harvested and then frozen to assess cytokine production within
treatments. Tumor necrosis factor α (TNFα), interleukin-6 (IL-6), and Toll-like receptor 2
(TLR-2) were evaluated using the ELISA. TNFα and IL-6 ELISA kits were purchased
from Biolegend (San Diego, Ca, USA) and the TLR-2 ELISA was purchased from Abcam
(Cambridge, UK). In summary, each plate was coated with primary antibody and kept at
4°C overnight. The next day the plates were washed followed by a blocking step with
FBS. The plates were washed again followed by addition of samples and standards.
After the allotted time, the plates were washed and detection antibody was added,
followed by a wash step and the addition of HRP solution. Lastly, a final wash was
completed and TMB substrate was allowed to interact with the HRP in the dark for 15
minutes. Stop solution was added and the endpoint absorbance was read at 450 nm.
Synthesis of the Unnarmicin D Analog. The cyclo (R-3-hydroxydecanoyl-Gly-D-TyrGly-Phe) peptide was synthesized by Peptides International through manual synthesis
and solution chemistry. The structure was verified by TOF-MS and 1H NMR. Purity was
determined using HPLC-UV and 1H NMR. Synthetic unnarmicin D analog: 1H NMR (500
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MHz, DMSO-d6) δ 9.21 (1H, s, Tyr-OH), 8.93 (1H, d, J = 5.8 Hz, Tyr-NH), 8.56 (1H, m,
Gly-2-NH), 7.97 (1H, dd, J = 8.2, 4.8 Hz, Gly-1-NH), 7.39 (1H, d, J = 9.3 Hz, Phe-NH),
7.22 (2H, m, H-6/8), 7.20 (2H, m, H-5/9), 7.16 (1H, m, H-7), 7.11 (2H, d, J = 8.5, H16/20), 6.68 (2H, d, J = 8.5, H-17/19), 5.12 (1H, m, H-25), 4.56 (1H, td, J = 9.5, 5.0 Hz,
H-2), 4.13 (1H, m, H-13), 3.88 (1H, dd, J = 17.1, 8.2 Hz, H11a); 3.82 (1H, dd, J = 14.7,
3.8, H-22a), 3.49 (1H, dd, J = 14.7, 6.7, H-22b), 3.36 (1H, dd, J = 17.0, 4.6, H-11b), 3.14
(1H, m, H-3a), 3.00 (1H, m, H-14a), 2.77 (2H, ovlp, H-3b/14b), 2.58 (1H, dd, J = 13.7,
3.5, H-24a), 2.17 (1H, dd, J = 13.6, 10.2, H-24b), 1.52 (1H, m, H-26a), 1.44 (1H, m, H26b), 1.26 (2H, m, H-31), 1.25-1.22 (6H, ovlp, H-28-30), 1.16 (2H, m, H-27), 0.85 (3H, t,
J = 7.0, H-32).
Base Hydrolysis of Unnarmicin D. 0.5 M sodium methoxide was prepared by
dissolving 27 mg of sodium methoxide power (Fisher Scientific) into a glass vial with 1
mL of methanol as a diluent. 5 mg of the synthetic unnarmicin D cyclic peptide was
added to the sodium methoxide solution. A sand bath was brought to 50°C, and the vial
containing the peptide was placed in the sand bath and stirred for 12 h. The reaction
was quenched with ca. 2 mL of chromatography grade water and stirred for an additional
5 min. A partition of DCM and water resulted in 3.2 mg of crude reaction mixture. The
product was re-isolated on the HPLC using an analytical C18 semi-preparative column
(Phenomenex) and the following gradient method: 0-5 minutes 40% ACN, 5-13 min 40100% ACN, 14-20 minutes 40% ACN (Figure S10). The HPLC product was monitored at
210 nm, 228 nm, and 254 nm.
Hydrolyzed synthetic unnarmicin D analog: 1H NMR (500 MHz, MeOH-d4) δ 7.23 (2H, m,
H-6/8), 7.22 (2H, m, H-5/9), 7.20 (1H, m, H-7), 7.03 (2H, t, J = 8.5 Hz, H-16/20), 6.69
(2H, d, J = 8.5 Hz, H-17/19), 4.53 (1H, m, H-2), 4.45 (1H, m, H-13), 3.96 (1H, m, H-25),
3.80 (4H, ovlp, H-11/H-22), 3.20 (1H, m, H-3a), 3.05 (1H, m, H-14a), 2.80 (2H, ovlp, H-
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3b/H-14b), 2.35 (2H, m, H-24), 1.48 (2H, m, H-26), 1.24-1.34 (10H, m, H27-H31), 0.89
(3H, t, J = 7.0 Hz, H-32).
Molecular Modeling. Molecular Docking. X-ray crystal structures for the mu opioid
receptor (6DDF, 4DKL)66 and the delta opioid receptor (4N6H, 6PT2, 4EJ4)60 were
downloaded from the protein data bank (PDB). Molecular docking studies were carried
out using Molecular Operating Environment.67 All X-ray crystal structures discussed
were prepared using MOE QuickPrep and receptor-ligand complexes were energy
minimized prior to Docking. Triangle Matcher was used for the docking placement
method with London dG for the score at 30 poses. Rigid Receptor was used for the
docking refinement method with GBCIWSA dG for the score at 5 poses. The SiteFinder
tool was used to determine statistically relevant binding sites for each ligand in the mu
and delta opioid receptors.
MOR and DOR Radioligand Binding Assay. The unnarmicin D synthetic analog was
tested at several concentrations to determine IC50 and Ki values of the peptide for both
MOR and DOR by Eurofins Cerep. Compound binding was calculated as a percent
inhibition of the binding activity of a radioactively labeled ligand specific for each target
detected by scintillation counting (MOR, DAMGO; DOR, DPDPE). The tests were carried
out in human recombinant cells (MOR, Chem-1 cells; DOR, HEK-293 cells). Percent
inhibition of control specific binding was determined for each concentration tested. IC50
values were determined by non-linear regression analysis of the competition curves
using Hill equation curve fitting and inhibition constants (Ki) were calculated using the
Cheng Prusoff equation.
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ABSTRACT
Introduction: Cannabinoids including cannabidiol (CBD) have attracted enormous
interest as a bioactive ingredient for potential dermatological and/or cosmeceutical
applications. However, there is a lack of fundamental knowledge on the skin permeability
of CBD and its topical formulations. Herein, we aimed to evaluate the skin permeability
of CBD and CBD in a cream formulation using artificial membrane assays.
Materials and Methods: CBD and its formulations’ skin permeability was assessed
using artificial membrane-based models including the parallel artificial membrane
permeability assay (PAMPA) and the Franz cell diffusion (in vitro release testing) assay.
Results: CBD isolate showed favorable skin permeability in the PAMPA assay (with a LogPe value of 5.019 and 5.021, at pH of 6.5 and 7.4, respectively), which was
supported by data from the Franz cell diffusion assay (51.8 μg CBD released over 8
hours). In addition, CBD had feasible solubility (378 μg), stability (81% stability at pH 5),
in the presence of surfactant Tween-20. CBD topical cream formulations also showed
promising skin permeability in the Franz cell diffusion assay (25.2 μg CBD released over
8 hours).
Conclusion: Findings from the current study suggest that CBD is a skin permeable
cannabinoid, and the permeability of its formulations may be influenced by several
factors including surfactant, pH environment, and stability. Further biological evaluations
using in vivo models are warranted to confirm these activities.
Keywords: Cannabidiol, skin permeability, PAMPA, Franz cell, cosmetics.

Abbreviations used:
CBD – Cannabidiol
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PIB – polyisobutene
SLS- sodium lauryl sulfate
(w/w) – weight per weight
T20 – tween 20
T80 – tween 80

INTRODUCTION
The skin is the largest organ in the human body.1 It is composed of various layers
of cells that together act as a barrier to keep unwanted biological and chemical
constituents from permeating and entering the body.2 The avascular outermost layer of
the skin, called the epidermis, is comprised of keratinocytes, Merkel cells, melanocytes,
and Langerhans cells, which participate in the protection against inflammation and
immunological responses.2,3,4 The most superficial layer of the epidermis is the stratum
corneum, which is the most difficult layer to permeate and is the rate-limiting step in the
penetration process. Below the epidermis is the vascular dermis layer, which contains
additional cell types such as fibroblasts but also free nerve endings which play a
significant role in pain sensation. 2,3 Proper formulations for skin cosmeceutical products
can result in active ingredient delivery to a specific location such as muscles or blood
vessels, and transdermal formulations can result in absorption and systemic circulation
of the active component to achieve prolonged delivery.5
Due to the recent legalization and decriminalization status of the medicinal plant
Cannabis sativa, as well as a general shift towards more natural ingredients in skincare,
there has been a large increase in the use of Cannabis metabolites in skincare
products.6 Cannabis sativa is a member of the Cannabaceae plant family. This annual
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herbaceous plant has many phytochemicals unique to members of this genus, which are
referred to as phytocannabinoids. The two most abundant phytocannabinoids are
cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) ( Figure 1).7 THC is
responsible for the psychoactive effects of the Cannabis plant, whereas CBD is the main
non-psychoactive cannabinoid.8 The human body also contains endogenous
cannabinoid molecules, termed endocannabinoids, which are an integral part of the
endocannabinoid system such as N-arachidonoylethanolamine (anandamide) and 2arachidonoylglycerol.9,10 The main molecular targets of the endocannabinoids are the
cannabinoid receptors 1 and 2 (CB1 and CB2).11 Much of the focus of THC has focused
on the effects in the central nervous system where CB1 receptors are localized, and
CBD research has largely focused on the anti-inflammatory effects involving CB2
receptors located in the peripheral nervous system and immune cells.12 CBD is a weak
modulator to both cannabinoid receptors but it can modulate the release of
endocannabinoids, as well as act on additional receptors such as the transient receptor
potential vanilloid type 1 (TRPV1) and various G-protein coupled receptors.8 The
location of the cannabinoid receptors within the body ultimately determines the
physiological reaction. The ECS in the skin is involved in various biological processes
such as the proliferation, differentiation, and immune tolerance within the various types
of skin cells.4,13 Every cell type produced by the skin relies on components of the
endocannabinoid system, this includes the expression of cannabinoid receptors 1 and 2
on keratinocytes, hair follicles, and sebaceous glands.14,15 Disruption and dysregulation
in the ECS within the skin cells can lead to skin diseases.16 Other important receptors
such as the TRPV1 receptor is also highly expressed in epidermal skin cells, which
facilitates the activity of CBD.17
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F4 1 Figure 1: The chemical structure of cannabidiol (CBD) (A) and delta-9
tetrahydrocannabinol (Δ-9 THC) (B) isolated from the plant Cannabis sativa.

The medicinal benefits of CBD can be enhanced by combining CBD with THC or
CBD given alone can stimulate the release of the endocannabinoid anandamide by
inhibiting the FAAH (fatty acid amide hydrolase) enzyme.15 Both the FAAH enzyme,
which is responsible for degrading and recycling anandamide, and the MAGL
(monoacylglycerol lipase) enzyme, which is responsible for removing 2-AG are also
highly expressed in various constituents of the skin.18 Activation of CB1 receptors on the
skin surface by phytocannabinoids can have therapeutic implications for diseases such
as psoriasis and eczema due to the role that the endocannabinoid system plays in
inflammation and immunity.19 Furthermore, cannabidiol has antioxidant properties that
protect the skin from oxidative stress on the epidermis caused by UVA/UVB radiation
from the sun. Exposure to UVA and UVB rays shifts redox imbalance towards oxidation
and ultimately leads to an increase in reactive oxygen species (ROS), which leads to
cellular damage.20
Plant extracts and metabolites have been used for centuries as the active
ingredient in creams and salves. In the 1880s Dr. Carl Koller found the local anesthetic
properties of cocaine creams useful for cataract extractions and today various plant
extracts are incorporated into cosmeceutical formations.21
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Recently, CBD has become a popular ingredient in skincare products, asserting
anti-inflammatory, analgesic, hydration, and other benefits from the incorporation of this
molecule. With celebrity endorsements, this is projected to become an industry worth
between $135 and $155 billion (USD) globally by 2021.22 One concern with the
incorporation of cannabinoids in skincare products is the susceptibility of these
metabolites to aerobic oxidation, causing a color change from a clear solution to a
yellowish-brown solution resulting in the formation of hydroxyquinone.23 There remains a
gap in understanding quantitatively the stability of CBD in solution, as well as the
permeability of CBD in different skincare formulations. Understanding how to formulate
skincare products in a way that increases the storage and stability of phytocannabinoids
as well as increasing the permeation through the skin is critical. Furthermore, it is
important to determine the rate at which cannabinoids passively diffuse across the skin
to establish the time that would be required between dosing regimens and identify
potential targets for skin therapeutics. A comprehensive understanding of the
physiology of the skin as well as a physicochemical understanding of the active
compound is necessary for proper formulation of products to reach the target tissue. The
stability and permeability of CBD can be investigated using various in vitro assays, and
this information will further our understanding of this popular cosmetic ingredient for
future formulation studies and ensure safety and efficacy for product use.
MATERIALS AND METHODS
Reagents
Cannabidiol (CBD; purity 99.46%) was obtained from DB Labs (Las Vegas, NV, USA).
The cellulose and Strat-M® membranes for Franz cell assay and ethanol were
purchased from Millipore Sigma (Burlington, MA, USA). Supor PES membranes, pore
size 0.1 and 0.45 μM were purchased from Pall Corporation (Port Washington, NY,
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USA). Phosphate buffer saline was purchased from Sigma-Aldrich Co. (St. Louis, MO,
USA). All materials for PAMPA were purchased from Pion, Inc. (Billerica, MA, USA).
Silky Cream Base (BAS-SLKC-01) natural gel base (BAS-NATGE-01), polyisobutene,
mineral oil, phytosqualane and propylene glycol were purchased through Making
Cosmetics Inc. (Redmond, WA, USA). Polysorbate 20 NF was purchased from LetCo
Medical (Decatur, Al, USA). Polysorbate 80 was purchased through Fisher Scientific
(Waltham, MA, USA). Sodium lauryl sulfate was purchased through Gallpot (St. Paul,
Mn, USA). Regent free water was purchased from Corning (Corning, NY, USA).
Simulgel NS was purchased from Seppic Inc. (Fairfeild, NJ, USA). Oleyl alcohol
ethoxylate was purchased from Croda (Snaith, UK).
High-Performance Liquid Chromatography (HPLC) Analysis
Samples containing lipophilic surfactant were prepped for HPLC analysis using a C-18
100 mg (part no: 12102001) solid phase extraction (SPE) column were purchased through
Agilent Technologies (Salta Clara, CA, USA) to remove residual surfactant. Analytical
HPLC was carried out using a Dionex UltiMate 3000 HPLC system equipped with a micro
vacuum degasser, an autosampler, and a diode-array detector. Cannabidiol was
quantified using high performance liquid chromatography. HPLC analysis was performed
with an Thermo C18 column (250 × 4.6 mm, 5 μm) and a solvent system consisting of
0.05% formic acid in water (A)/Acetonitrile (B) was used as the mobile phase using a 9
minute isocratic method at 80% B and a flow rate of 0.6 mL/min.
LC-MS method
Various PAMPA samples were analyzed using both LC-UV and LC-MS analysis
(Thermo Fisher ISQ system paired with a Dionex HPLC system). LC-MS analysis was
performed with an Thermo C18 column (250 × 4.6 mm, 5 μm) and a solvent system
consisting of 0.05% formic acid in water (A)/Acetonitrile (B) which was used as the
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mobile phase with a 15 minute isocratic method at 80% B and a flow rate of 0.6 mL/min
(Figure S1)
Cannabidiol Stability in Solution
The stability of CBD in a pH adjusted aqueous solution was determined through a
stability test. Cannabidiol in 10% tween 20 (w/w) was added to PBS buffer that was
adjusted to pH 4,5,6 and 7 . Each solution was prepared to a final concentration of 200
µg/ml of CBD. Solutions were left at room temperature and constant light for 30 days.
Samples of solution were taken at different time points. The concentration of CBD in
solution was quantified using HPLC analysis and a linear regression of areas under the
curve. (Figure S7)
Cannabidiol Surfactant Solubility
A panel of 4 surfactants, polyisobutene (PIB), polysorbate 20 (tween 20), polysorbate 80
(tween 80) and sodium lauryl sulfate (SLS) were evaluated for their potential to solubilize
cannabidiol in an aqueous solution (Figure S5,Figure S6). Each solution was prepared at
surfactant concentrations of 1, 2, 5 or 10% (w/w); the final surfactant concentration used
in the experiment was 10% (w/w). In a falcon tube, 5 mg of Cannabidiol and surfactant
was added to 12 mL of phosphate buffer saline (PBS) or phosphate buffer (PB).
Solutions were shaken and left at room temperature for 24 hours. Solutions that did not
have visible precipitation of cannabidiol were prepared for HPLC analysis using SPE and
concentrations were evaluated using a standard linear regression (Figure S7).
Parallel Artificial Membrane Permeability Assay (PAMPA)
Pion’s suggested procedures were followed as stated in the instruction manual, version
4. Briefly, test compounds and standards were prepared at 10 mM concentrations in
DMSO. In the deep well plate provided by Pion, 1 mL of each pH adjusted buffer was
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added to separate wells. For each pH, 5 µL of the 10 mM the 10 mM sample was added
to 1 mL of pH adjusted buffer then mixed thoroughly with a pipette, diluting the sample to
a final concentration of 50 µM. 200 µl of the diluted sample was added to the donor
(bottom) plate from the Pion sandwich assay. Next, 200 µL of acceptor sink buffer was
added in each well of the acceptor plate. The sandwich was assembled, and the plate
was incubated at room temperature, with stirring for 5 hours undisturbed. After
incubation, the UV profiles of the donor and acceptor plates were read on the
SpectraMax plate reader connected to the PAMPA software. PAMPA software
calculated the –log Pe values for each compound and standard using the UV profiles of
the donor and acceptor plates. Standards were all within 0.25 of the expected value
provided by PAMPA and each sample was averaged with 6 replicates for each pH
tested.

Formulations of CBD creams
Two creams were used to evaluate CBD permeability in solution. The first, a
commercially available cream from makingcosmetics.com was a silky cream base (BASSLKC-01). CBD isolate powder (1% w/w) was added directly to this base and emulsified
on a shearing instrument for 2.5 minutes. The second cream was formulated using
ingredients in the compounding lab at the University of Rhode Island. The cream
contained equal parts propylene glycol, phytosqualene and mineral oil to comprise 50%
(w/w) of the total formulation. CBD isolate powder (1% w/w) was added directly to the
propylene glycol, mixed thoroughly and added to the other oils. Next the surfactant,
simulgel ns (7%) was added to the lipophilic phase mixture, followed by reagent free
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water (42%). The cream was homogenized on a shearing instrument for 2.5 minutes.
Each formulation was tested for physical evaluation between the thumb and index finger
to ensure a smooth texture and no signs of phase separation. Formulations were then
centrifuged 9 times at 5000 rpm in 5-minute intervals to confirm stability. Both
formulations were stable and did not fully separate into 2 phases after centrifugation.
Franz Cell Diffusion Assay
One day prior to the assay, the receptor buffer was prepared in 50 mL falcon tubes and
pre-warmed in a water bath at 32 °C overnight. 3% (w/w) surfactant was used in 1x PBS.
Surfactant concentration was determined after solubility analysis. Tween 20 showed the
best solubility for CBD (Figure S5). Depending on membrane brand and type, cellulose
acetate membranes were hydrated one day prior to running the assay by submerging
the membrane in 1x PBS in a beaker with parafilm covering the top (Figure S1). On the
day of the assay, the Franz cell water bath was also pre-warmed to 32°C 30 minutes
prior to beginning. After the water had been warmed, the pre-soaked membranes were
applied to the apparatus using forceps. Next, 12 mL of acceptor buffer was added via
pipette into each Franz cell, and 1 mL of pure CBD in DMSO or 200 mg of cream was
added using a syringe. The tops of the cells were clamped and covered in parafilm to
prevent evaporation. At each given timepoint, 600 µL of sample was removed from the
spout of the Franz apparatus and replaced with 600 µL of fresh buffer.
The In Vitro Release Testing (IVRT) Data Analysis
Each 600 μL acceptor well example for IVRT analysis was first run through a C18 SPE
column to remove any surfactant from the sample. Samples were then analyzed via
HPLC, and the area under the curve (AUC) for the CBD peak was recorded. Elution time
was compared with that of the CBD in the standard curve (Figure S8). A linear
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regression of CBD standards was calculated (R2= 0.9759) and concentrations of CBD
were interpolated. For the initial timepoint collected in the Franz cell assay, the formula
used to calculate CBD released amount (drug concentration/1000 *12). For each
timepoint following, the calculation was adjusted to account for the addition of fresh
buffer added at each time point, for these timepoints the equation (drug
concentration*12+0.6*(sum of sample concentrations)/1000) was used.
RESULTS
CBD shows favorable skin permeability in the PAMPA assay
The skin permeability coefficient, Log Kp (cm/s) was used to evaluate the theoretical
permeability of CBD through the skin (Table 1). This value was determined using an
online computational model, SwissADME. CBD is considered to have moderate skin
permeability with a Log Kp value of -3.59 cm/s. The positive PAMPA skin controls,
warfarin, piroxicam, progesterone and verapamil all exhibited low skin permeability in the
SwissADME predictor (Table S1). After this predictive measure, compounds were
experimentally evaluated for passive permeability in the skin.

T3 1 Table 1: In silico SwissADME predictive permeability of cannabidiol in the skin.

sample

-Log Kp

Log Po/w

( cm/s)
Cannabidiol

-3.59

-Log S

-Log S (Ali)

(ESOL)
3.90

-5.69

-7.17

(CBD)

Compounds were evaluated for their permeability through a theoretical skin membrane
using PAMPA at pH 6.5 and 7.4 (Figure 2). Warfarin was used as our low permeability
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standard verapamil and piroxicam were used as our medium permeability standards,
progesterone was used as our high permeability standard, and a pH control standard
was also run. CBD showed similar permeability at both pH 6.5 and 7.4 with -LogPe
values of 5.0194 ± 0.083 and 5.021 ± 0.045 respectively, suggesting it has moderate
skin permeability.

F4 2 Figure 2: CBD shows passive permeability in the Skin PAMPA model. The passive
permeability of CBD was evaluated at two relevant pH levels 6.5 (A) and 7.4 (B). The
controls warfarin and piroxicam exhibit low permeability, while progesterone and
verapamil exhibit medium permeability. -Log Pe values for CBD at pH 6.5 and 7.4 were
determined to be 5.0194 ± 0.083 and 5.021 ± 0.045 respectively. (n=6).
CBD is soluble in surfactant Tween 20
CBD solubility in an aqueous solution was evaluated using four surfactants at a final
concentration of 10% w/w (Figure 3). The concentration of CBD in solution that did not
come out of solution or crystallize was determined using HPLC analysis. Although no
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apparent precipitation was observed, Polyisobutene (PIB) experienced minimal amount
of CBD solubility in both PB and PBS buffer having 33.7 and 47.3 µg/mL of CBD in
solution respectively (Figure S6). The concentrations of CBD in sodium lauryl sulfate and
tween 80 solutions were also comparable to that of tween 20 (Appendix B). CBD
solutions containing 10% tween 20 and PBS buffers were considered the ideal
surfactant-solvent system, due to relatively high solubility and reproducibility. This
solution contained about 378.4 μg of CBD per mL.

F4 3 Figure 3: Tween 20 is the ideal surfactant to solubilize CBD in an aqueous
solution Polyisobutene showed the least solubility potential for CBD in both PBS and
PB buffer. The concentrations are expressed as mean ± standard error (n=3), statistical
significance was determined by analysis of variance (ANOVA). Significance as
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compared with tween 20, p ≤ 0.01 (*), p ≤ 0.001 (**), p ≤ 0.0001 (***) and p ≤ 0.00001
(****).

CBD in Tween 20 is skin permeable
The theoretical skin permeability of pH adjusted CBD surfactant solutions was
determined using PAMPA (Figure 4). Concentrations of CBD in the acceptor wells were
determined using LC-MS analysis after 5 hours. CBD showed the least permeability in
pH 5 with a maximum concentration of about 4.9 μg/mL. In contrast, CBD in the ideal
surfactant-solvent solutions showed the most permeability at pH 7 with 7.4 μg/mL
permeated.

F4 4 Figure 4: CBD-Surfactant solution shows passive permeability at various
pH’s. Assessment of skin passive permeability of CBD-Tween 20 solution determined
via PAMPA. CBD exhibited variable permeability with pH change. Data is expressed as
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mean ± standard error (n=3), statistical significance was determined by analysis of
variance (ANOVA). Statistical significance between each pH (P=0.0039).

CBD in Tween 20 is stable at pH of 5
The stability of CBD in an aqueous solution was evaluated to determine the percent
degradation of CBD at different pH’s (Figure 5). The stability suggests the optimal pH
range of formulations containing CBD. Concentration of CBD was determined through
HPLC analysis and quantified through a standard linear regression. CBD was added to a
pH adjusted solution of PBS with 10% Tween 20 (w/w). Overall, CBD in solution showed
the least amount of degradation at pH 5 with a cumulative degradation of 19% over 30
days. In contrast, CBD in pH 7 solution showed the most degradation with 48.5%
degrading over the 30-day period. CBD in pH solutions 4 and 6 showed similar trends
with a degradation of about 30% and 29% over the 30 days respectively.

F4 5 Figure 5: CBD is most stable at pH 5. The stability of a CBD-surfactant solution
was evaluated at four pH’s 4, 5 , 6 and 7 . Degradation was confirmed through the
accumulation of breakdown products and was expressed as percent cumulative
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degradation over a 30-day timespan. Concentrations are expressed as mean ± standard
error (n=3), statistical significance was determined by analysis of variance (ANOVA) with
significance as compared with Day 0.
In Vitro Permeation Test
The permeability of CBD through a theoretical skin membrane was evaluated using the
Franz cell diffusion model (Figure 6). Concentrations of permeated CBD were
determined through HPLC analysis of the acceptor well. CBD showed passive diffusion
through the theoretical skin membrane and reached its maximum diffusion concentration
of 51.9 μg at 6 hours.

F4 6 Figure 6: In vitro permeability profile of Cannabidiol (CBD) in sterile DMSO obtained
using Franz diffusion cells (n = 9).

In Vitro Release Testing of CBD Formulations
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The in vitro CBD release of two different cream formulations was tested using the Franz
cell diffusion assay (Figure 7). The final CBD content in the formulations was
approximately 1% (w/w). The cream formulation (200 mg) of cream was loaded onto
each cellulose acetate membrane, HPLC analysis was taken of the acceptor well
following each timepoint. CBD showed passive diffusion through a theoretical skin
membrane in a cream formulation. Further analysis is necessary to ensure CBD
permeability through human skin.

F4 7 Figure 7: In vitro release profiles of CBD formulations obtained using Franz
diffusion cells (n=3). The in vitro drug release profiles of CBD EmulGel Cream (A) and
CBD making cosmetics cream (B).
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DISCUSSION
Cannabidiol’s extensive use in cosmetics necessitates further evaluation into the
stability and permeability of this metabolite through the skin. Cannabinoids are
susceptible to UV degradation, chemical rearrangements, and oxidation.24 Lindholst
determined that when organic solvents, such as ethanol and chloroform are used, both
temperature and light exposure influence the stability of cannabinoids.25 However, most
of the studies that have been completed investigate the resin forms of Cannabis or the
alcohol extracts. In skincare, alcohol extracts with solvent present and pure resin are
rarely used. Rather, the lipophilic cannabinoids would be incorporated into aqueous
based products using surfactants, or simply added to creams without surfactants. It is
well established that light and temperature play the most significant role in
degradation.25,26 We found that in a PBS and 10% w/w Tween 20 solution, which is more
relevant in skincare formulations than alcoholic preparations, CBD shows the most
degradation at pH 6 and pH 7 compared to pH 4 and pH 5 (Figure S7). Many skincare
products are already formulated to be slightly acidic, often using ingredients such as
citric acid to maintain barrier function of the acid mantle on the skin.27
CBD was evaluated with multiple in vitro assays to evaluate the passive
permeability of CBD through biomimetic skin membranes. The first assay employed was
the parallel artificial membrane permeability assay (PAMPA). Using this method, CBD
permeability was compared to the control compounds provided with the assay with wellestablished pharmacokinetics. CBD showed a similar permeability profile with the
endogenous steroid progesterone. A -Log Pe of 5.0194 was measured for the pH of 6.5,
and a -LogPe of 5.021 at pH 7.4 suggesting CBD is moderately permeable through the
skin. This aligns well with the results from the in silico prediction software SwissADME
which predicted the permeability to be -3.59 (cm/s).
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Conceptually similar to PAMPA, the Franz cell diffusion assay was employed to
determine the rate at which CBD penetrated synthetic skin membranes using in vitro
release testing (Figure S8). After completion of a membrane compatibility test (Figure
S3), SUPOR PES membranes were the most compatible with CBD, and the membranes
did not interfere with the release of the compound. Commercially available gel and
cream bases were purchased from makingcosmetics.com for initial evaluation for
permeability studies. Due to the popularity of CBD creams, and the higher penetration,
only creams were evaluated further in this study (Figure S2). When comparing
formulations of CBD in a commercially available formulation and an in-house
formulation, emul-gel cream, the in vitro release testing indicated the release of CBD in
our formulation was much higher compared to the Making Cosmetics Inc. cream (Figure
7). Discrepancies in permeability may be due to non-uniformity of CBD in formulation of
the commercially available cream due to the order of incorporation of the CBD later in
the formulation process compared to cream formulated in our laboratory where CBD can
be incorporated into an oil medium prior to addition of other ingredients. Quantification of
CBD initial concentrations in the commercially available product indicated that CBD
isolate powder was not fully dissolved into the formulation. Excipient concentration for
the making cosmetics cream is proprietary. A larger aqueous phase may account for
discrepancies in uniformity and could allow for CBD to crash out of solution. This issue
may be avoided in the future with the use of a carrier oil that is compatible with both the
drug and formulation. Conversely, CBD isolate powder was added directly to the
lipophilic phase of the emul-gel cream and concentrations of CBD in formulation were
within expected range. The way in which this emul-gel cream was formulated likely
affected both stability and permeability of CBD in formulation. Permeability may have
also been influenced by the presence of penetration enhancing oils in the lipophilic
phase of the emul-gel cream. Propylene glycol, an excipient used in formulating, has
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been shown to enhance transdermal drug permeability.28 PAMPA analysis of the
compounds at pH 6.5 and 7.4 showed similar permeability patterns (Figure 6). When
different surfactants were used in the PAMPA assay, a difference in pH permeability
dependence was observed. Tween 20 and Tween 80 showed better solubility at pH 6
and pH 7 compared to those at the lower pH values tested. Sodium lauryl sulfate
showed significantly better permeation at pH 7 compared to the other pH values (Figure
S4)
CONCLUSION
Cannabidiol’s popularity in cosmeceuticals warrants an investigation into the
stability and permeability through artificial skin membranes. In this study, CBD showed
moderate skin permeability in the PAMPA assay using both the pure compound and
cream formulations. The stability of CBD can be increased by keeping the product cool,
out of light, and at lower pH. At pH 5, CBD is the most stable in a solution of PBS with
Tween 20 as a surfactant. Highly lipophilic cream formulations should be considered for
deeper penetration of CBD. Further evaluation is necessary to assess CBD permeability
in human skin.
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PERSPECTIVE
As previously known diseases evolve and progress, or new diseases emerge, we
look to the diverse chemistry of nature for new therapeutics. Natural products have been
used for centuries in traditional Chinese medicine, Ayurvedic medicine, Native American
medicine and more, and there remains a significant number of untapped sources.
However, natural product extracts are extremely chemically diverse and it is essential to
have methodologies in place to highlight drug candidates and weed out other
metabolites as early as possible. Employing these methodologies early in the drug
screening process can save billions of dollars, thousands of animals’ lives, and hundreds
of hours of precious time.
Screening natural product libraries for drug leads is a valuable tool for increasing
the chances of a hit from either a single metabolite or a family of metabolites. The value
of this drug screening pipeline can be enhanced when orthogonal assays are
incorporated into the drug screening that consider common roadblocks in the drug
development pipeline. Evaluating a drug candidates permeability through biological
membranes is an integral component of drug development, and recent tools have been
developed for in vitro analysis. The development of the Principal Rhode Island
Secondary Metabolite (PRISM) library from the plants in the University of Rhode Island’s
Heber W. Youngken Jr. Medicinal Plant Garden was the first step towards developing a
screening platform. The utility of the PRISM library was then demonstrated through
antimicrobial testing of two persistent pathogens Staphylococcus aureus and
Escherichia coli. A metabolite isolated from the tulip tree (Liriodendron tulipifera) named
laurenobiolide showed promising activity as a terpene antibiotic to combat methicillin
resistant S. aureus infections and a metabolite from saffron (Crocus sativus) showed
promising activity in reversing bacteria quiescence, a phenomenon contributing to
persistent and reoccurring UTIs.
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Not every assay is compatible with crude extract testing. In the case of cell
culture assays for example, it is much simpler to either have a pure compound library or
some rarified mixtures of compounds. The benefit of evaluating a mixture of compounds
includes less time spent in the process of generating the library and an increased
chance of discovering a new chemical entity with bioactivity. This was demonstrated in
workflows evaluating a cyanobacteria chromatography library for anti-inflammatory
potential. Two new members of the micropeptin family were discovered as antiinflammatory peptides.
My research has also combined multiple methods of library screening within the
same pipeline; this included in silico screening for drug likelihood, in vitro screening for
permeability, and in vitro screening for bioactivity. This resulted in the discovery of a
cyanobacteria metabolite, unnarmicin D which acts as a delta and mu opioid ligand with
anti-inflammatory properties to murine microglia cells. These results could have further
implications in the fight against the opioid epidemic as delta opioid agonists are less
addictive pain alternatives to the traditional mu opioidactivators such as morphine as
well as a way to combat the development of neurodegenerative diseases.
Lastly, the commonly used cosmeceutical metabolite from the Cannabis sativa
plant cannabidiol, contributes millions of dollars in sales of skincare supplements
annually, but the permeability through the skin has not been well evaluated. Two in vitro
assays were utilized to determine the passive permeability of CBD through the skin,
which will have implications in future product formulations.
These data combined provide insight into multiple diseases and the
methodologies discussed herein can be applied to a variety of synthetic and small
molecule natural products. Moreover, these results support the initial hypothesis that
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early incorporation of permeability screening into drug discovery workflows will enhance
the output towards the discovery of more pharmacologically relevant metabolites.
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Supporting Information: Integrating Natural Product Chemistry Workflows into
Medicinal Chemistry Laboratory Training: Building the PRISM Library and
Cultivating Independent Research
Riley D. Kirk, Marina A. Carro, Christine Wu, Mohamad Jamal Aldine, Alex M. Wharton,
Danielle G. Goldstein, Margaret E. Rosario, Gina M. Gallucci, Yiwen Zhao, Elizabeth
Leibovitz, Matthew J. Bertin*

A1 1 Figure S1. Summary of teaching lab and research lab workflows.
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A1 2 Figure S2. Comparison of anti-oxidant activity between aerial and root methanol
extracts of Echinacea purpurea. Quercetin was used as a positive control.

A1 3 Figure S3. Comparison of anti-oxidant activity among the chromatography fractions
generated from Echinacea purpurea root methanol extract. SPE 1 clearly showed
strongest anti-oxidant activity and was chosen for further HPLC and MS experiments.
Quercetin was used as a positive control.
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A1 4 Figure S4. Comparison of initial and improved HPLC chromatograms of St. John’s
Wort sample. HPLC methods are shown at right.
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A1 5 Figure S5. Mass spectrum of Berberrus thumbergii sample indicating the likely
presence of berberine m/z 336.

A1 6 Figure S6. Analysis of St. John’s Wort samples by the afternoon teaching lab
group. TIC and UV analysis at 210 nm and 254 nm are shown. MS analysis identified a
metabolite with m/z 487 as the major metabolite, which was putatively identified as
isoquercetin.
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A1 7 Figure S7. Analysis of St. John’s Wort samples by the morning teaching lab group.
TIC and UV analysis at 210 nm and 254 nm are shown. MS analysis identified a
metabolite with m/z 487 as the major metabolite, which was putatively identified as
isoquercetin.

135

A1 8 Figure S8. Antioxidant bioassay plates from both the morning hops group (left
plate) and the afternoon hops group (right plate). The plates tested three SPE fractions
with quercetin used as a positive control. Concentrations begin at 1 mg/mL in row A and
decrease 2-fold in each row of the plate moving toward the bottom of the plate. Both
groups identified SPE 1 as the fraction with the strongest antioxidant activity. The SPE 1
fraction was analysis by LC-UV-MS by both groups (see Figures S9 and S10).
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A1 9 Figure S9. LC-UV-MS chromatograms of SPE 1 fraction from both the morning and
afternoon groups who were studying hops extracts (UV = 254 nm). Mass spectra of the
major peaks (highlighted in pink) are shown in Figure S10. Methods were identical in
morning and afternoon groups.

A1 10 Figure S10. MS spectra of the major peaks from LC-UV-MS analysis, which was
shown in Figure S9 (peak highlighted in pink). Many identical ions can be observed in
the spectra from the morning and afternoon hops groups.
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Screening the PRISM Library for anti-bacterial compounds against a resistant
Staphylococcus aureus strain and a uropathogenic E.coli strain

Riley D. Kirk1, Josiah Morrison 2, Christine Wu1, Marina A. Carro1, Elizabeth Leibovitz1,
Nana Oblie1, Matthew J. Bertin1*
1

Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy,
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A2 1 Figure S1: HPLC chromatogram of the crude methanol extract of the tulip tree

(Liriodendron tulipifera). Mobile phase consisted of water and acetonitrile with 0.5%
formic acid. The method was 70 minutes long with a 10 minute hold on the starting
conditions of 15% CH3CN: 85% H2O, followed by a gradient which ended at 45 minutes,
followed by a 100% organic hold for 20 minutes and a 5 minute reconditioning phase at
the starting conditions.
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A.

B.

C.
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A2 2 Figure S2: (A) The initial antibacterial disc diffusion assay highlighted two main
peaks in the lipophilic fractions of the tulip tree, upon isolation of each peak, the later
eluting peak showed the most antibacterial activity towards S. aureus. (B) The purity of
both major peaks was checked on a phenyl hexyl column. Peak 1 was a single pure
compound, and peak 2 was two distinct peaks. The isocratic method was 55%
CH3CN /45% H2O with 0.05% formic acid added to each solvent at a flow rate of 3
mL/min (C) The three isolated peaks were re-tested to determine the active compound.
Peak 2.1 was determined to be the active compound, the other compounds did not show
anti-MRSA activity. Methanol was used as the diluent and the negative control.
Gentamicin sulfate was used as the positive control. Left plate is dosed at 20 µg and
right plate is dosed at 5 µg.

A2 3 Figure S3: 13C NMR spectrum of peak 2 (500 MHz, DMSO-d6) prior to separation
via phenyl hexyl column, showing an abundance of signals compared to what would be
expected for a 17 carbon metabolite.
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A2 4 Figure S4: 1H NMR spectrum of peak 1, identified as epi-tulipinolide (500 MHz,
CDCl3).
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A2 5 Figure S5: 1H NMR spectrum of peak 2.1, identified as laurenobiolide (500 MHz,
CDCl3).
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A2 6 Figure S6: 1H NMR spectrum of peak 2.2, identified as tulipinolide (500 MHz, CDCl3).

A2 7 Figure S7: High resolution mass spectrometry measurement of laurenobiolide,
measuring m/z of 313.1418.
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A2 8 Figure S8: HPLC chromatogram highlighting the active antibacterial compound
laurenobiolide, monitored at 210 nm in the various parts of the Liriodendron tulipifera
tree.
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A2 9 Figure S9: Results of E. coli quiescent activation testing with PRISM library
samples. Positive control consists of co-spotting lysine and methionine at 1 mM. 69.3%
of extracts tested (79/114) showed some level of quiescent reversing activity, the
remaining 30.7 % of extracts did not. Samples were prepared at 10 mg/mL in (CH3)2SO
with 10 µL spots.

A2 10 Figure S10: Separation of saffron fraction 20% H2O: 80% CH3CN using HPLC
with fraction collector. Four pools of compounds were collected for retesting on the
quiescence assay (blue shaded areas). The method used a C18 semi-preparative
column with water and acetonitrile as the mobile phase. Gradient method beginning at
15% CH3CN to 50% CH3CN.
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A2 11 Figure S11: Individual compounds were isolated from the active fraction pool.
Method consisted of water and acetonitrile as the mobile phase with 0.5% formic acid.
Gradient method of 5% CH3CN

30% CH3CN. A Phenomenex phenyl hexyl

semipreparative column was used for isolation. Fraction 1 was identified as the active
following a quiescence reversal assay.
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A2 12 Figure S12: Compounds isolated from fraction 1 showing compounds 4 and 5 with
the most potent quiescence reversing activity. Samples were tested at 1 mg/ mL with 10
µL spots.
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A2 13 Figure S13: Titration of compound 4 (upper left) and compound 5 (upper right)
from Crocus sativus. Compound 4 showed the strongest activity when the dose was
titrated to 0.125 mg/mL.
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A2 14 Figure S14: HRESIMS analysis of the active compound 4.

A2 15 Figure S15: MS/MS spectrum of the active compound 4 fragmenting the precursor
m/z 319.1486.

A2 16 Figure S16: 1H NMR spectrum of the active compound 4 (500 MHz, DMSO)
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New Micropeptins with Anti-Neuroinflammatory Activity Isolated from a Cyanobacterial
Bloom
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Table S1. NMR data for micropeptin 957 (500 MHz for 1H NMR, DMSO-d6) (2).
Figure S1. Structures of micropeptins 982 (1), 957 (2), and 996.
Figure S2. Cell viability of Biosortia chromatography fractions tested against BV-2
murine microglial cells.
Figure S3. Ability of Biosortia chromatography fractions to reduce nitric oxides species
(NOS) in BV-2 murine microglial cells.
Figure S4. Full MS/MS network of fraction D29. Analysis was performed using the
software available at the GNPS: Global Natural Product Social Molecular Networking
website. Node size is indicative of ion count.
Figure S5. HPLC isolation of compounds in chromatography fraction D29.
Figure S6. Final purification of compounds 1 (6.1) and 2 (6.2) from fraction D29 peak 6.
Figure S7. 1H NMR spectrum of micropeptin 996 (500 MHz, DMSO-d6).
Figure S8. 13C NMR spectrum of micropeptin 996 (125 MHz, DMSO-d6).
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Figure S9. HRESIMS of micropeptin 996, m/z 1019.4854 [M+Na]+.
Figure S10. MS/MS of micropeptin 996.
Figure S11. 1H NMR spectrum of micropeptin 982 (1) (500 MHz, DMSO-d6).
Figure S12. 13C NMR spectrum of micropeptin 982 (1) (125 MHz, DMSO-d6).
Figure S13. HSQC spectrum of 1.
Figure S14. HMBC spectrum of 1.
Figure S15. COSY spectrum of 1.
Figure S16. TOCSY spectrum of 1.
Figure S17. NOESY spectrum of 1.
Figure S18. HRESIMS of micropeptin 982 (1), m/z 1005.4698 [M+Na]+.
Figure S19. MS/MS of micropeptin 982 (1).
Figure S20. 1H NMR spectrum of micropeptin 957 (2) (500 MHz, DMSO-d6).
Figure S21. COSY spectrum of 2.
Figure S22. TOCSY spectrum of 2.
Figure S23. NOESY spectrum of 2.
Figure S24. HRESIMS of micropeptin 957 (2), m/z 980.4858 [M+Na]+.
Figure S25. MS/MS of micropeptin 957 (2).
Figure S26. Marfey’s analysis of micropeptin 982 (1).
Figure S27. Marfey’s analysis of micropeptin 957 (2).
Figure S28. Dose-responses of micropeptin 996, 1, and 2 tested for plasmin inhibition.

STA1 1 Table S1. NMR data for micropeptin 957 (500 MHz for 1H NMR, DMSO-d6) (2).

Position
Val-1
2

δH, mult, J (Hz)

COSY/TOCSY

4.66, m
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3
4
5
NH
N-MeTrp-1
2
3a
3b
4
5
NH
6
7
8
9
10
11
N-Me
Phe-1
2
3a
3b
4
5/9
6/8
7
Ahp-1
2
3a
3b
4a
4b
5
NH
OH
Val-2
2
3
4
5
NH
Thr-1
2
3
4
NH

2.00, m
0.84, d (6.8)
0.70, d (6.8)
7.42 (ovlp)

4,5
3
3
2

5.11, m
3.30, ovlp
2.99, m

3a, 3b
2, 3b
2, 3a

7.14, ovlp
11.01. m

NH
5

6.55, d (8.4)
6.90, d (8.3)
7.40, m
7.58, d (7.9)

8
7,9
8,10
9

2.78, s
4.72, ovlp
2.83, m
1.66, ovlp

3a,3b
2,3b
2,3a

6.78, d (7.2)
7.17, d (7.4)
7.13, m

6,8
5,9

3.59, m
2.33, m
1.61, m
1.68, m
1.50, m
5.00, ovlp
7.04, d (9.6)
5.85, br

3b,Ahp-NH
3b,4b
2,3a
3a,4b,5
3a,4a,5
4a,4b,Ahp-OH
2
5

4.70, ovlp
2.10, ovlp
0.88 d (6.8)
0.74, d (6.5)
7.31, ovlp

Val-2-NH
2,4,5
3
3
2

4.53, d (9.5)
5.37, m
1.10, d (6.5)
7.47, d (9.5)

Thr-NH
4
3
2
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Gln-1
2
3a
3b
4
5
NH
NH2
BTA-1
2
3
4

4.30, ovlp
1.85, m
1.65, m
2.10, ovlp

3a,3b,Gln-NH
4
4
3a, 3b

8.13, d (7.7)
7.28, br

2

2.11, ovlp
1.57, m
0.90, t (7.4)

3
2,4
3

Figure S1. Structures of micropeptins 982 (1), 957 (2), and 996. Key 2D NMR
correlations are shown for 1 and 2. Additionally, NOE correlations are shown for the Ahp
residue in 1 and 2, which were used to assign relative configuration.
A5 1
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A5 2 Figure S2. Cell viability of Biosortia chromatography fractions tested against BV-2
murine microglial cells.
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A5 3 Figure S3. Ability of Biosortia chromatography fractions to reduce nitric oxides
species (NOS) in BV-2 murine microglial cells.
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A5 4 Figure S4. Full MS/MS network of fraction D29. Analysis was performed using the
software available at the GNPS: Global Natural Product Social Molecular Networking
website. Node size is indicative of ion count.

156

A5 5 Figure S5. HPLC isolation of compounds in chromatography fraction D29.
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A5 6 Figure S6. Final purification of compounds 1 (6.1) and 2 (6.2) from fraction D29
peak 6.
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A5 7 Figure S7. 1H NMR spectrum of micropeptin 996 (500 MHz, DMSO-d6).
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A5 8 Figure S8. 13C NMR spectrum of micropeptin 996 (125 MHz, DMSO-d6).
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A5 9 Figure S9. HRESIMS of micropeptin 996, m/z 1019.4854 [M+Na]+.
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A5 10 Figure S10. MS/MS of micropeptin 996.
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A5 11 Figure S11. 1H NMR spectrum of micropeptin 982 (1) (500 MHz, DMSO-d6).
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A5 12 Figure S12. 13C NMR spectrum of micropeptin 982 (1) (125 MHz, DMSO-d6).
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A5 13 Figure S13. HSQC spectrum of 1.

A5 14 Figure S14. HMBC spectrum of 1.
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A5 15 Figure S15. COSY spectrum of 1.
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A5 16 Figure S16. TOCSY spectrum of 1.
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A5 17 Figure S17. NOESY spectrum of 1.

A5 18 Figure S18. HRESIMS of micropeptin 982 (1), m/z 1005.4698 [M+Na]+.
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A5 19 Figure S19. MS/MS of micropeptin 982 (1).

A5 20 Figure S20. 1H NMR spectrum of micropeptin 957 (2) (500 MHz, DMSO-d6).
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A5 21 Figure S21. COSY spectrum of 2.
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A5 22 Figure S22. TOCSY spectrum of 2.
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A5 23 Figure S23. NOESY spectrum of 2.

A5 24 Figure S24. HRESIMS of micropeptin 957 (2), m/z 980.4858 [M+Na]+.
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A5 25 Figure S25. MS/MS of micropeptin 957 (2).

L/D-Phe

L-Phe

Hydrolysate

A5 26F

Figure S26. Marfey’s analysis of micropeptin 982 (1) with L-phenylalanine

determination shown at right
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L-Val

A5 27

L/D-Val

Hydrolysate

Figure S27. Marfey’s analysis of micropeptin 957 (2) with L-valine determination shown
at right.

Figure S28. Dose-responses of micropeptin 996, 1, and 2 tested for plasmin inhibition.
A5 28
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APPENDIX D: Supplementary Materials for Chapter 4

Unnarmicin D, an anti-inflammatory cyanobacterial metabolite with delta and mu
opioid binding activity discovered via a pipeline approach designed to target
neurotherapeutics
Riley D. Kirk, Kassie Picard, Joeseph A. Christian, Shelby L. Johnson, Brenton DeBoef,
Matthew J. Bertin

STA3 1 Table S1: Trichodesmium metabolites SWISS ADME profiles with conditional formatting
for pharmacokinetic data.

STA3 2 Table S2: Metabolites of interest based on in silico screening. Two polyketides
and one cyclic peptide were highlighted as the most likely to be drug candidates based
on analysis of various physiochemical parameters that contribute to drug-like molecules.
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STA3 3 Table S3: Neurotherapeutic target predictions for the top ADME metabolites.
The three drug-like molecules from SWISS ADME were further evaluated using SWISS
Target Predictor. Focusing only on neuropharmacological targets, the small polyketide,
tricholactone (GH2I1), showed a low probability of being a dopamine transporter.
Trichophycin B (EF1E) showed low to moderate probability of being a noradrenaline
transporter, serotonin transporter, and/or a dopamine transporter. Unnarmicin D
(GH2C1) showed moderate to high probability of containing opioid receptor binding
activity to either the delta or mu opioid receptor.

STA3 4Table S4: Multiple-reaction-monitoring transitions

Compound

MRM-transition (parent ion/product ion)

Theophylline 181/110
Verapamil

455/289

GH2D8

499/330

GH2N1

616/598

GH2C1

623/163
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STA3 5 Table S5: All RMSD, S-values, and PLB values for molecular modeling data. Red highlight
indicates the best binding probability for the test compound.
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A3 1 Figure S1: SWISS target prediction of unnarmicin D as a GPCR ligand.
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A3 2 Figure S2: The fractionation workflow for cyanobacteria collections. Crude extract
is obtained then subjected to repeat extractions using 2:1 DCM:Methanol followed by
further rareification into fractions A-I using vacuum liquid chromatography and stepped
gradients of hexanes, ethyl acetate, and methanol. Fraction G was used to confirm the
permeability results from the pure compound PAMPA plate.
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A3 3 Figure S3: BV2 cell viability after treatment with cyanobacterial compounds. The
effects of the cyanobacteria metabolites on the viability of BV-2 cells was evaluated
using Cell Titer Glo assay. Cells were dosed with 10 µM, 5 µM and 1 µM of pure
compound for 24 hours then viability was measured compared to the control wells of
DMSO.
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A3 4 Figure S4: Structure comparison of the synthesized unnarmacin D analog and the
natural product. Due to limitations in compound unnarmicin D (GH2C1), the peptide was
synthesized. The synthetic compound and the originally isolated natural product are the
same structure except the 12-carbon lipophilic chain is a 10-carbon chain.
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A3 5 Figure S5: 1H NMR spectrum of the synthetic unnarmacin D analog (500 MHz,
DMSO).
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A3 6
Figure S6: Comparison of 1H NMR spectra of synthetic product and natural product.
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A3 7 Figure S7: Mass spectrometry of the synthesized unnarmicin D. The synthesized
peptide was analyzed by MS to confirm the protonated molecule m/z of 595.3695.
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A3 8 Figure S8: HPLC analysis of the unnarmicin D synthetic peptide.
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A3 9 Figure S9: Anti-inflammatory activity of linear unnarmicin D, the natural product,
and synthetic. Griess assay results showing the total NOS concentration in cell
supernatant after treatment with unnarmicin D derivatives at 5 µM for one hour followed
by LPS activation of BV2 cells for 24 hours. Significance as compared with synthetic
unnarmicin D using ANOVA with Dunnett’s multiple comparison procedure, p ≤ 0.03
(*), p ≤ 0.002 (**), p ≤ 0.0002 (***) and p ≤ 0.0001 (****). All three metabolites showed
significant of p ≤ 0.0001 compared to LPS.
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A3 10 Figure S10: Base hydrolysis of unnarmicin D results in a linear peptide. This
compound is similar in structure to the endogenous opioid Leu-Enkephalin.
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A3 11 Figure S11: HPLC analysis of the base hydrolyzed unnarmicin D.

A3 12 Figure S12: MS analysis of the base hydrolyzed unnarmicin D. The sodiated
molecule m/z of 635.2661 is shown.
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A3 13 Figure S13: 1H NMR spectrum of the base hydrolyzed synthetic unnarmicin D
(500 MHz, MeOH).
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A3 14 Figure S14: A.) The MOR (6DDF) binding interactions of the base hydrolyzed
synthetic unnarmicin D. B.) The DOR (4N6H) binding interactions of the base hydrolyzed
synthetic unnarmicin D.

A3 15 Figure S15: Unnarmicin D modeled in the binding pocket of three DOR crystal
structures. A.) The agonist bound conformation, PDB 6PT2, B.) The antagonist bound
conformation, PDB 4EJ4, C.) The non-ligand bound conformation, PDB 4N6H.
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A3 16 Figure S16: Unnarmicin D derivatives modeled with a methyl group in place of the
lipophilic tail for both the Mu opioid receptor (6DDF) (A.), and the Delta opioid receptor
(4N6H) (B.).

A3 17 Figure S17: A-B. The agonist bound MOR (PDB 5C1M) with water molecules
present. C-D.The unbound DOR receptor (4N6H) with water molecules and a sodium ion
present in the receptor pocket.
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A3 18 Figure S18: Histogram of values representing the agonist radioligand binding of
Unnarmicin D to the MOR and the DOR showing the pIC50 for each receptor.

A3 19 Figure S19: Radioligand binding assay for unnarmicin D on the delta opioid
receptor. Test concentration and mean percent inhibition of control DPDPE specific
binding values.
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A3 20 Figure S20: Radioligand binding assay for unnarmicin D on the mu opioid
receptor. Test concentration and mean percent inhibition of control DAMGO specific
binding values.
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A3 21 Figure S21: Radioligand binding assay comparison of the synthetic linear
unnarmicin D and the synthetic cyclic unnarmicin D ligands in the delta opioid receptor.
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A3 22 Figure S22: 1H NMR spectrum of the natural product unnarmicin D (GH2C1).

195

A3 23 Figure S23: 1H NMR spectrum of tricholide A (EF1J).
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A3 24 Figure S24: 1H NMR spectrum of tricholide B (EF1K).
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A3 25 Figure S25: 1H NMR spectrum of smenamide C (GH2H1).
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A3 26 Figure
S26: 1H NMR spectrum of smenamide E (GH2D8).
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A3 27 Figure S27: 1H NMR spectrum of smenothiazole A (EF1C1A).
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A3 28
Figure S28: 1H NMR spectrum of isoconulothiazole B (EF1F2A).
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A3 29 Figure S29: 1H NMR spectrum of conulothiazole C (I2F2A).
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A3 30 Figure S30: 1H NMR spectrum of trichophycin B (EF1E).
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A3 31 Figure S31: 1H NMR spectrum of trichophycin F (GH3K1).
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A3 32 Figure S32: 1H NMR spectrum of tricholactone (GH2I1).
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A3 33 Figure S33: 1H NMR spectrum of trichophycin C (D2D2).
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A3 34 Figure S34: 1H NMR spectrum of trichotoxin A (D2E1).
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A3
35Figure S35: 1H NMR spectrum of trichotoxin B (D2F1).
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A3 36 Figure S36: 1H NMR spectrum of GH2N1.
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A3 37
Figure S37: HPLC-UV analysis of I3IJ2.
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APPENDIX E: Supplementary Materials for Chapter 5
Supplementary Information:
STA4 1 Table S1: in silico SwissADME predictive permeability and -Log Pe values of
PAMPA standards.
STA2 1

PAMPA
Standard

Expected
-Log Pe
(PAMPA)

-Log
Kp
(cm/s)

Log
Po/w

-Log S
(ESOL)

-Log
S (Ali)

Warfarin

-6.00

-6.26

2.41

-3.70

-3.77

Piroxicam

-5.67

-6.15

1.67

-4.01

-4.99

Verapamil

-5.65

-6.38

4.50

-4.46

-4.83

Progesterone

-4.92

-5.47

3.09

-4.16

-4.28
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Figure S1. CBD PAMPA LC-MS Chromatogram. The passive permeability of CBD
through a theoretical skin membrane was determined using the PAMPA assay. The
presence of CBD in the acceptor buffer was determined through LC-MS analysis and
confirmed with an m/z of 315. CBD was quantified using standard linear regression.
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Figure S2. CBD stability test HPLC chromatogram. The stability of CBD in surfactant-buffer
solution. The degradation of CBD in a surfactant-buffer solution was confirmed through HPLC
analysis, using a standard elution time ~6 minutes and UV detection of 210 nm. CBD
degradation was monitored from day 0 (1) to day 30 (2). Degradation of API was confirmed
through reduction of CBD peak area and the accumulation of degradative product peaks eluting
before CBD. CBD was quantified using standard linear regression.
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Figure S3: CBD solubility in potential Franz cell acceptor buffers. A solution of PBS
buffer containing 3% (w/w) tween-20 (T20) was determined to be the optimal solvent
system that allows for the passive diffusion of CBD through a synthetic membrane.
Solvent systems containing ethanol (Etoh) and Oleyl alcohol ethoxylate (OAE) at various
concentrations did not reach full solubility capacity.
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Figure S4. CBD solubility test HPLC chromatogram. CBD in a 10% (w/w) poly
isobutene – PBS buffer solution (1), 10% (w/w) poly isobutene – PB buffer solution (2)
and a 10% (w/w)Tween 20-PBS solution (3) were evaluated to determine the ideal
surfactant solvent system to solubilize the API. The amount of CBD in solution was
determined through HPLC analysis and quantified using standard linear regression.
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A4 1 Figure S5: The permeability profile of CBD in 10% tween-20 surfactant solution
through a cellulose membrane using a Franz diffusion assay. N=3.
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Figure S6.CBD IVRT HPLC chromatogram. CBD Showed passive permeability in the
Franz Cell diffusion assay. The permeability profile of CBD through a synthetic skin
membrane was determined using the Franz cell diffusion assay. The presence of CBD
was confirmed through HPLC analysis, using the average elution time of ~7.2 minutes
and UV detection of 210 nm. At each time point 30 minutes (1), 1 hour (2), 2 hours (3), 4
hours (4) and 6 hours (6), CBD was quantified using standard linear regression.
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A4 2 Figure S7: CBD compatibility test using the Franz cell assay (n=3). Receptor buffer
was a 3% tween 20 in PBS solution at 32°C.
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A4 3
Figure S8: In vitro release testing (IVRT) of CBD in commercially available cream silky
cream (BAS-SLKC-01) and gel (BAS-NATGE-01) formulations (Making cosmetics) in the
Franz cell assay, (n=3). CBD formulation permeability was achieved with the use of a
10% (w/w/) tween-20 carrier vehicle.
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A4 4
Figure S9: CBD-Surfactant solution shows passive permeability in various pH’s.
Assessment of skin passive permeability of CBD-Tween 80 & and CBD- Sodium Lauryl
Sulfate solution determined by PAMPA. CBD exhibited variable permeability with pH
change. Data is expressed as mean ± standard error (n=3).

A4 5
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